US 9,737,400 B2Grant

Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets

Issue Date:2017-08-22

•85 Claims

•29 Drawing Sheets

Abstract

A transcatheter, percutaneously implantable, prosthetic heart valve is provided that comprises a lattice frame and two or more integrated cusp and leaflet folded structures attached to the lattice frame. The two or more integrated cusp and leaflet folded structures each comprise a flat sheet of biocompatible membrane that is folded to include a substantially conical shape according to a flat folding pattern. The substantially conical shape is further formed by joining apposing sides of the substantially conical shape along a seam. The two or more integrated cusp and leaflet folded structures are each attached along their respective seams to the lattice frame in a direction substantially parallel to an axis of the lattice frame. Embodiments of valves described herein have application within the entire vascular system.

Metadata

Assignee

COLIBRI HEART VALVE LLC

Inventors

R. David Fish
Eduaro Induni
David Paniagua

Application Information

Application Number:US 13/326,196

Filing Date:2011-12-14

Priority Date:2010-12-14

Art Unit:3738

Classifications

IPC:

A61F2/24

Field of Search:

A61F 2/24A61F 2/82

Patent Drawings (29 sheets)

Description

Cross-Reference to Related Application

[0001] The present application claims the benefit of U.S. Provisional Patent Application No. 61/423,051 filed on Dec. 14, 2010, the content of which is incorporated herein by reference in its entirety.

Field

[0002] The present invention relates to the field of medical devices, and more particularly, to percutaneously deliverable heart valves.

Background

[0003] The native heart valves, and in particular, the aortic valve, has a complex geometry that endows both ideal opening and closing geometries through an anatomic joining of a tubular inflow structure of the left ventricular outflow tract and an expansion of the valve sinuses above the hinging point of the valve leaflets defined by the aortic valve annular ring, part of the fibrous “skeleton” of the heart.

[0004] For the purposes of discussion and definition in the ensuing descriptions, the “upper”, downstream outlet structure of the native aortic valve above its hinging point contains three valve “cusps” of a generally spherical contour with central mobile portions termed “leaflets” that are induced by fluid pressure gradients to meet centrally to close and to move radially outward to open in valve operation. The cusps are further continuous with downstream curved tissue walls meeting the tubular great vessel, the aorta, at the “sino-tubular junction”. Each cusp and its upper, downstream extension above the level of leaflet closure (“coaptation”) are a continuous structure of a generally spherical contour and together define the envelope of the “sinus of Valsalva”. Typically, surgical prosthetic valves are implanted by excision of the diseased native valve leaflets at the level of the annular ring, and suturing of the prosthetic valve at this point, thus replacing only the opening geometry of the valve and leaving the outer structures of the cusps and the sinuses of Valsalva, the anatomy that confers proper closing geometry, generally intact.

[0005] Surgical valve prostheses are generally constructed as analogs to this central portion of the native valve geometry involved in the opening phase of the valve cycle. This approach to modeling the replacement valve prosthesis is enabled by the nature of the surgical technique: the replacement valve is sutured into the valve seat under direct vision. In contrast, a percutaneous stent-mounted heart valve (“PHV”) is typically a construct in which the operating valve membrane leaflets are mounted and confined within the tubular envelope of a collapsible frame for effective transvascular delivery.

[0006] Further, in order to preclude valve regurgitation, the base of each leaflet must lie in exact apposition to the valve seat to form a seal, a condition that is difficult to satisfy without implantation under direct vision. Even then, since the diseased native valve would not be removed and its axial geometry is often distorted, it may not be possible to seat a PHV exactly under any circumstances. Thus, a cylindrical cuff layer, interior or exterior to the frame, is usually employed that acts as a seal and provides some latitude in the positioning and alignment of the PHV along the axis of flow, allowing for reliable and effective PHV implantation and minimizing the risk of significant valve regurgitation. Finally, the diseased native valve leaflets, when pushed outward by the deployed PHV frame, may themselves form a barrier separating the sinuses of Valsalva from the leaflets of the PHV, then disrupting the native closing geometry of the valve so that the sinuses are no longer continuous with the pressurized space above the PHV leaflets.

[0007] These issues illustrate some of the challenges to the formation of a PHV; that is, how to confine operating leaflets within a partially sealed tubular structure while preserving ideal opening and closing valve behavior without the benefit of the natural mechanism of the sinuses of Valsalva in a single valve and leaflet geometry, such as the separate and distinct upper and lower geometries of the native valve. As such, there is a need for additional devices, systems and/or methods that address one or more of the problems or shortcomings noted above.

Summary

[0008] It is to be understood that the present invention includes a variety of different versions or embodiments, and this Summary is not meant to be limiting or all-inclusive. This Summary provides some general descriptions of some of the embodiments, but may also include some more specific descriptions of other embodiments.

[0009] Two goals of at least some embodiments of the present inventions are: (1) to maximize effective orifice area and minimize opening pressure gradients through geometry that mimics the natural form of inflow into the valve—the tubular outflow tract of the heart pumping chamber; and (2) to minimize the inward tension on the leaflet commissures in the closed position through geometry that mimics the natural effect of the sinuses of Valsalva—an effect that prevents downward displacement of the leaflet free edges under closing pressure, thus distributing force along the lines of leaflet apposition rather than focusing it at the points of leaflet attachment to the frame.

[0010] The first of these goals dictates that the inflow to the valve, similar to that of the natural aortic valve, encounters then outwardly displaces the most central portion of the leaflets first, with opening moving progressively outward along the surface of the leaflets. The second suggests that the cross-sectional profile of the valve sinus/cusp formed in its central portion by the free edge of the leaflets, like that of the natural aortic valve, should be approximately elliptical, and that the cross-sectional diameter of each cusp should progressively decrease below the plane of leaflet apposition, like that of the natural valve cusps. One or more embodiments of the one or more present inventions answer the configuration ideals with a robust balance of functional geometries for valve opening and closing.

[0011] The spherical geometry of the native aortic valve leaflets is difficult to replicate in a transcatheter valve. First, while this shape is functionally robust in vivo, even if reproduced in some form it is not suited to efficient radial compression typically required for collapse into a small diameter delivery catheter used in transcatheter valve delivery systems, and discontinuities would develop in the leaflet surface that would resolve into irregular folds with at least some circumferential component, thereby threatening the restitution of the geometry on reopening at deployment. Second, tissue bioprosthetic valve leaflets, if not actually constituted of the animal valve itself, are typically constructed of flat sheet tissue membrane from which rendering of cusps with leaflets of a spherical contour would be difficult if not impossible without the use of traction force on the material, or extensive cutting and suturing of the leaflet cusp portion—an impractical approach, and a threat to the material integrity of the thin tissue membrane.

[0012] At least one embodiment of the one or more present inventions answers these challenges by employing conical rather than spherical cusp geometry, thereby reproducing some benefits of the latter with near-elliptical leaflet cross-section that progressively decreases moving proximal to the plane of leaflet apposition while being readily conformed on outward radial compression in the valve opening phase into a substantially flat folded construct against the interior tubular walls of the containing frame. This favorable resolution of the conical geometry in opening phase expresses the opening efficiency of this valve design with a large effective orifice area and low transvalvular energy losses. In the closed position, the free edges of the separate leaflets of the conical cusps meet in apposition, each cone acting as an independent valve; pressure load-bearing is enhanced by the material continuity of the cone structure with the inner apposing wall and outer wall of each cone being part of a single continuous membrane structure. Further, the conical cusps are particularly suited for compression and containment within a collapsible frame for transcatheter delivery.

[0013] In at least one embodiment, a transcatheter, percutaneously implantable, bioprosthetic heart valve having a lattice frame comprising a substantially tubular alloy metal mesh, and two or more valve cusps with leaflets mounted to the lattice frame, is provided. Further, the cusps include a flat sheet of processed mammalian tissue membrane that is folded into a substantially conical shape according to a flat folding pattern, the substantially conical shape is further formed by joining opposing sides of the substantially conical shape along a seam that is oriented along a longitudinal axis of the substantially conical shape. In at least one embodiment, the two or more cusps are attached along their seams (which may or may not include the apexes of the cusps), such as, by way of example and not limitation, along the axial centerline of the outer circumference of the cone, to an interior portion of the lattice frame along an axial flow direction of the valve and are further attached along the distal, downstream, edge of the substantially conical shape along at least an outer half of the substantially conical shape's edge. When the membrane valve leaflet is attached to the frame, its principal line of securement along the axial centerline of the outer circumference of the cone is attached at a non-commissural seam or edge, effecting a coaxial (to the flow axis) line of attachment at an area of the structure that advantageously bears load, thereby relieving the commissural attachment of loads associated with the securement of the cusp structures to the frame. As such, the leaflet commissure attachments, thus located at points where the leaflet membrane is continuous and uncut, advantageously need only bear the centripetal loads associated with the radially inward movement and operation of the free edges of the leaflets.

[0014] In at least one embodiment, a transcatheter, percutaneously implantable, bioprosthetic heart valve is provided wherein two distal, downstream, vertices of the flattened cusp and leaflet structure are folded over in a radially outward direction and fixed to the frame such that the vertex folds of neighboring leaflets are adjacent and define an extent of leaflet apposition at the points corresponding to leaflet commissures.

[0015] In at least one embodiment, a transcatheter, percutaneously implantable, bioprosthetic heart valve is provided wherein a vertex forming a proximal, upstream, apex of the substantially conical shape is folded over in a radially outward direction and affixed to an inner portion of the frame.

[0016] In at least one embodiment, a transcatheter, percutaneously implantable, bioprosthetic heart valve is provided wherein the flat folding pattern is polygonal and includes extending portions that, when the leaflet is mounted, extend circumferentially outward from an axial line of attachment of the leaflet to the frame so as to form, when joined and attached to corresponding extending portions of neighboring leaflets, an integral, inner, luminal, circumferentially partial or complete sealing cuff.

[0017] In at least one embodiment, a transcatheter, percutaneously implantable, bioprosthetic heart valve is provided wherein a separate tubular sealing cuff of tissue membrane is attached to an outer, abluminal surface of the frame to form a sealing cuff. In at least one embodiment, the membrane sheet is a single layer of a substantially homogenous material. In at least one embodiment, the membrane sheet is an unlaminated single layer of material. In at least one embodiment, the membrane sheet is a single layer of material that does not include any reinforcement, such as reinforcing fibers. In at least one embodiment, the membrane sheet is a single layer of treated pericardium tissue. In at least one embodiment, the membrane sheet is a single layer of a synthetic film.

[0018] Therefore, in accordance with at least one embodiment, a transcatheter, percutaneously implantable, prosthetic heart valve is provided, comprising:

- [0019] a lattice frame; and
- [0020] two or more integrated cusp and leaflet folded structures attached to the lattice frame, the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of biocompatible membrane that is folded to include a mobile leaflet layer and a cusp wall layer, wherein the cusp wall layer located radially outside of the mobile leaflet layer, and wherein the cusp wall layer is further formed by joining apposing sides of the cusp wall layer along a seam. In accordance with at least one embodiment, the two or more integrated cusp and leaflet folded structures are each attached along their respective seams to the lattice frame. In accordance with at least one embodiment, the seams are oriented in a direction substantially parallel to an axis of the lattice frame. In accordance with at least one embodiment, the flat sheet of biocompatible membrane forming at least one integrated cusp and leaflet folded structure of the two or more integrated cusp and leaflet folded structures comprises two or more pieces of biocompatible membrane material.

[0021] In accordance with at least one embodiment, a transcatheter, percutaneously implantable, prosthetic heart valve is provided, comprising:

- [0022] a lattice frame; and
- [0023] two or more integrated cusp and leaflet folded structures attached to the lattice frame, the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of a biocompatible membrane that is folded to include a valve cusp according to a flat folding pattern, wherein the valve cusp is further formed by joining apposing sides of the valve cusp along a seam, and wherein the two or more integrated cusp and leaflet folded structures are each attached along their respective seams to the lattice frame in a direction substantially parallel to an axis of the lattice frame. In accordance with at least one embodiment, two distal, downstream, vertices of the integrated cusp and leaflet folded structure are folded over as vertex folds in a radially outward direction and fixed to the lattice frame such that the vertex folds of circumferentially adjacent leaflets are adjacent and define a degree of leaflet apposition at the points corresponding to leaflet commissures. In accordance with at least one embodiment, the two distal, downstream, vertices are fixed to the lattice frame by attachment not along an alignment with the vertex folds. In accordance with at least one embodiment, a vertex forming a proximal, upstream, tip of the substantially conical shape is folded over in a radially outward direction and attached to an inner portion of the lattice frame. In accordance with at least one embodiment, the flat folding pattern is polygonal and includes extending portions that, when the cusp is mounted, extend circumferentially outward from an axial line of attachment of the cusp to the frame so as to form, when joined and attached to corresponding extending portions of neighboring cusps, an integral, inner, luminal, circumferentially complete sealing cuff. In accordance with at least one embodiment, the flat folding pattern is polygonal and includes extending portions that, when the two or more cusps are mounted, extend circumferentially outward from an axial line of attachment of the cusp to the lattice frame so as to form a circumferentially incomplete sealing cuff portion associated with each cusp. In accordance with at least one embodiment, a separate tubular sealing cuff of biocompatible membrane is attached to an outer, abluminal surface of the lattice frame to form a sealing cuff. In accordance with at least one embodiment, the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as tubular stent member. In accordance with at least one embodiment, the biocompatible membrane comprises processed mammalian pericardium tissue. In accordance with at least one embodiment, the biocompatible membrane does not comprise a treated tissue. In accordance with at least one embodiment, the biocompatible membrane comprises a synthetic material. In accordance with at least one embodiment, the seams of the two or more integrated cusp and leaflet folded structures are each oriented along an axis of flow of the valve. In accordance with at least one embodiment, the two or more integrated cusp and leaflet folded structures are each further attached to a circumferential portion of the lattice frame along at least a portion of their distal downstream edges. In accordance with at least one embodiment, the two or more integrated cusp and leaflet folded structures are attached to the lattice frame at least at a non-commissural seam aligned with an axial flow direction of the valve.

[0024] In accordance with at least one embodiment, a transcatheter, percutaneously implantable, prosthetic heart valve is provided, comprising:

- [0025] a lattice frame; and
- [0026] two or more integrated cusp and leaflet structures attached to the lattice frame, the two or more integrated cusp and leaflet structures each comprising a flat sheet of biocompatible membrane that is folded to include a mobile leaflet layer and a cusp wall layer, wherein with the mobile leaflet layer in a closed position a transverse cross-sectional area of a cusp-sinus space decreases monotonically from a distal end to a proximal end of the mobile leaflet layer. In accordance with at least one embodiment, the cusp wall layer is located radially outside of the mobile leaflet layer. In accordance with at least one embodiment, the cusp wall layer is further formed by joining apposing sides of the cusp wall layer along a seam. In accordance with at least one embodiment, the mobile leaflet layer in the closed position a transverse cross-sectional length of the mobile leaflet layer decreases monotonically from a distal end to a proximal end of the mobile leaflet layer. In accordance with at least one embodiment, the mobile leaflet layer and the cusp wall layer of each integrated cusp and leaflet structure are a single continuous piece of biocompatible membrane.

[0027] At least one invention of the one or more present inventions is a novel integrated cusp and leaflet structure that has application for a variety uses, including implantable valves other than prosthetic heart valves. Accordingly, in at least one embodiment, and in subcombination, an integrated cusp and leaflet structure for attachment to a lattice frame to form a valve configured for implantation in a vascular system of a patient is provided, the integrated cusp and leaflet structure comprising:

- [0028] a flat sheet of biocompatible membrane that is folded to include a mobile leaflet layer and a cusp wall layer, wherein the cusp wall layer is divided along a seam, and wherein the mobile leaflet layer is continuous and apposes the cusp wall layer when the integrated cusp and leaflet structure is pressed substantially flat. In accordance with at least one embodiment, the mobile leaflet layer and the cusp wall layer of the integrated cusp and leaflet structure are a single continuous piece of biocompatible membrane. In accordance with at least one embodiment, the biocompatible membrane comprises a synthetic material. In accordance with at least one embodiment, the integrated cusp and leaflet structure further comprises at least one commissure tab. In accordance with at least one embodiment, the at least one commissure tab is configured for engaging a slot within a member of the lattice frame.

[0029] One or more embodiments of the one or more present inventions are also directed to methods for forming the inventive valves described herein, as well as its component elements. Accordingly, a method of forming an integrated cusp and leaflet folded structure for use in an implantable valve having an axial flow direction is provided, comprising: folding a flat sheet of biocompatible membrane to form an integrated cusp and leaflet folded structure according to a flat folding pattern, wherein said folding includes making two diagonal folds in the flat sheet of biocompatible membrane, the two diagonal folds separating a mobile leaflet layer from a cusp wall layer of the integrated cusp and leaflet folded structure. In accordance with at least one embodiment, the two diagonal folds are angled at between about 10 to 80 degrees from the axial flow direction. In accordance with at least one embodiment, the method further comprises forming first and second cusp wall folds, wherein the cusp wall layer is further formed by joining apposing membrane portions adjacent the first and second cusp wall folds along a seam that is oriented substantially parallel with the axial flow direction.

[0030] In addition to the foregoing, in accordance with at least one embodiment, a method of forming a transcatheter, percutaneously implantable, prosthetic heart valve is provided, comprising: folding a plurality of integrated cusp and leaflet folded structures, each integrated cusp and leaflet folded structure of the plurality of integrated cusp and leaflet folded structures comprising a flat sheet of biocompatible membrane that is folded to form a cusp according to a flat folding pattern, wherein the cusp is further formed by joining apposing sides of the cusp along a seam; and attaching each integrated cusp and leaflet folded structure of the plurality of integrated cusp and leaflet folded structures to a lattice frame, wherein the two or more integrated cusp and leaflet folded structures are each attached along their respective seams to the lattice frame in a direction substantially parallel to an axis of the lattice frame.

[0031] Various components are referred to herein as “operably associated.” As used herein, “operably associated” refers to components that are linked together in operable fashion, and encompasses embodiments in which components are linked directly, as well as embodiments in which additional components are placed between the two linked components.

[0032] As used herein, “at least one,” “one or more,” and “and/or” are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the expressions “at least one of A, B and C,” “at least one of A, B, or C,” “one or more of A, B, and C,” “one or more of A, B, or C” and “A, B, and/or C” means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together.

[0033] Various embodiments of the present inventions are set forth in the attached figures and in the Detailed Description as provided herein and as embodied by the claims. It should be understood, however, that this Summary does not contain all of the aspects and embodiments of the one or more present inventions, is not meant to be limiting or restrictive in any manner, and that the invention(s) as disclosed herein is/are understood by those of ordinary skill in the art to encompass obvious improvements and modifications thereto.

[0034] Additional advantages of the present invention will become readily apparent from the following discussion, particularly when taken together with the accompanying drawings.

Brief Description of the Drawings

[0035] To further clarify the above and other advantages and features of the one or more present inventions, a more particular description of the one or more present inventions is rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It should be appreciated that these drawings depict only typical embodiments of the one or more present inventions and are therefore not to be considered limiting of its scope. The one or more present inventions are described and explained with additional specificity and detail through the use of the accompanying drawings in which:

[0036] FIG. 1A is a plan view of a flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0037] FIG. 1B is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a folded membrane sheet after execution of the template foldings illustrated in FIG. 1A, thereby yielding a completed integrated cusp and leaflet folded structure;

[0038] FIG. 1C is a side perspective view directed radially outward of the inner aspect of an initially folded version of the integrated cusp and leaflet template shown in FIG. 1A;

[0039] FIG. 1D is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a further partially folded version of the integrated cusp and leaflet folded structure shown in FIG. 1C;

[0040] FIG. 1E is an another oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a further partially folded version of the integrated cusp and leaflet folded structure shown in FIG. 1D;

[0041] FIG. 1F is a modified version of the integrated cusp and leaflet folded structure shown in FIG. 1E;

[0042] FIG. 1G is same structure and view shown in FIG. 1E, along with a top (distal) cross-section schematic view of the distal end of a three-leaflet valve in a closed operating position;

[0043] FIG. 2 is a plan view of another flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0044] FIG. 3 is a plan view of yet another flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0045] FIG. 4 is a plan view of still yet another flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0046] FIG. 5A is a plan view of another flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0047] FIG. 5B is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a partially folded version of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 5A;

[0048] FIG. 5C is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a further partially folded version of the integrated cusp and leaflet folded structure shown in FIG. 5B;

[0049] FIG. 5D is plan view of the inner (luminal) aspect of a completely folded version of the structure of FIG. 5C, thereby yielding a completed integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 5A (with the exception of unfolded commissure tabs);

[0050] FIG. 5E shows a detail perspective view of a folded commissure tab;

[0051] FIG. 5F shows a perspective view of the outer (abluminal) aspect of the device shown in FIG. 5D;

[0052] FIG. 6 is a plan view of yet another flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0053] FIG. 7A is a plan view of still yet another flat sheet membrane template for the formation of an integrated cusp and leaflet folded structure in accordance with at least one embodiment of the one or more present inventions;

[0054] FIG. 7B is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a partially folded version of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A;

[0055] FIG. 7C is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of a further partially folded version of the integrated cusp and leaflet folded structure shown in FIG. 7B;

[0056] FIG. 7D is an oblique axial top (distal) perspective view directed downward (proximal) and radially outward of yet a further partially folded version of the integrated cusp and leaflet folded structure shown in FIG. 7C;

[0057] FIG. 7E shows a shallow oblique top perspective view of the outer (abluminal) aspect of the partially folded cusp and leaflet structure of FIG. 7D;

[0058] FIG. 7F is a plan view of the inner (luminal) aspect of a completely folded version of the structure of FIG. 7D yielding an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A (excepting that the commissure tabs and apex are not yet folded outward);

[0059] FIG. 7G is a side perspective view of the outer (abluminal) aspect of the structure of FIG. 7F showing a completely folded version of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A (excepting that the commissure tabs and apex are not yet folded outward);

[0060] FIG. 7H is a plan view of the inner (luminal) aspect of a completely folded version of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A;

[0061] FIG. 7I is a plan view of the outer (abluminal) aspect of a completely folded version of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A;

[0062] FIG. 7J is an oblique top (distal) perspective view of a completely folded version of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A;

[0063] FIG. 7K is a top perspective view directed downward (proximal) into the cusp space of an integrated cusp and leaflet folded structure prepared in accordance with the template shown in FIG. 7A;

[0064] FIG. 8A is an oblique top (distal) perspective view of an embodiment of a lattice frame for mounting three of the single-piece folded integrated cusp and leaflet structures as described herein;

[0065] FIG. 8B is a side elevation view of the lattice frame shown in FIG. 8A;

[0066] FIG. 8C is a side elevation view of the lattice frame of FIG. 8A with a superimposed plan view of the radially outer aspect of the completely folded integrated cusp and leaflet structure of FIG. 7I;

[0067] FIG. 8D is an oblique axial (top/distal) perspective view of an assembled three-leaflet valve in accordance with at least one embodiment;

[0068] FIGS. 9A and 9B are two different oblique axial (top/distal) perspective views of another embodiment of a lattice frame for mounting three of the single-piece folded integrated cusp and leaflet structures that include commissure tabs;

[0069] FIG. 9C is a side perspective view of the lattice frame shown in FIGS. 9A and 9B with a superimposed plan view of the outer aspect of the completely folded integrated cusp and leaflet structure of FIG. 7I;

[0070] FIG. 9D is a side view of the lattice frame shown in FIGS. 9A and 9B with superimposed views of the outer aspect of two circumferentially adjacent completely folded integrated cusp and leaflet structures; and

[0071] FIG. 9E is an oblique axial (top/distal) perspective view of an assembled three-leaflet valve comprising the lattice frame shown in FIGS. 9A and 9B and three identical folded integrated cusp and leaflet structures.

[0072] The drawings are not necessarily to scale.

Detailed Description

[0073] One or more embodiments of the one or more inventions described herein include an implantable prosthetic heart valve having a frame and two or more cusp and leaflet structures mounted to the frame. The frame preferably comprises a lattice of substantially tubular alloy metal mesh. The cusp and leaflet structures include a membrane operable to open and close, thereby providing a functioning valve when mounted within a frame. In at least one embodiment, the membrane preferably comprises a flat sheet of processed mammalian tissue membrane that is folded into a substantially conical shape according to a flat folding pattern.

[0074] In the ensuing descriptions and referenced figures it will be seen that, when applied to a dry sheet membrane, the folding initially results in a cusp shape of an inverted pyramid with a rhomboid base. On relaxation of the folds as occurs naturally with a flexible and pliable membrane, especially when the membrane is hydrated, the cusp shape becomes substantially conical in shape and will be described as such in the ensuing descriptions as it more closely represents the embodiment of the cusp in operation of the valve.

[0075] Formation of a valve construct as described herein provides a percutaneously deliverable heart valve with a relatively small diameter for transcatheter placement. That is, the substantially conical shape associated with the flat folding patterns used to form leaflets as described herein allow for construction of a valve that can be compressed prior to introduction to a catheter to an advantageously small diameter, thereby facilitating transcatheter percutaneous delivery of the valve within a patient. The substantially conical shape is further formed by joining two axially oriented sides of the substantially conical shape along a seam that is oriented along a longitudinal axis of the substantially conical shape. The two or more integrated cusp and leaflet structures are affixed to an interior portion of the lattice frame along an axial flow direction of the valve and are further affixed along the distal, downstream, edge of the substantially conical shape along at least an outer half of the substantially conical shape's edge.

[0076] One or more of the various embodiments described herein have a number of different features and characteristics as compared to other commercially available prosthetic heart valves. For example, at least one embodiment of a transcatheter, percutaneously implantable, prosthetic heart valve described below comprises a flat polygonal sheet membrane having more than four sides and which forms an integrated cusp and leaflet structure.

[0077] In addition, at least one embodiment of a transcatheter, percutaneously implantable, prosthetic heart valve described below comprises integrated cusp and leaflet structures that are attached to a lattice frame at the circumferential perimeter locations corresponding to the commissures. At such locations, the length of the seam that forms the common line of attachment of the cusp and integral leaflet to the frame is less than one-half to two-thirds of the axial length of the membrane portion of the valve.

[0078] In at least one embodiment of a transcatheter, percutaneously implantable, prosthetic heart valve, when the valve is in the open position, the mobile leaflet layer apposes or is geometrically free to appose its full outward surface completely to the immediately radially located outward structure, such as at least one of the cusp wall layer or interior surface of the lattice frame. In at least one embodiment, in the closed position the transverse cross-sectional length of the mobile leaflet layer and the cross-sectional area of the cusp/sinus space decreases monotonically from the distal end to proximal end of the membrane portion of the valve. (That is, generally the property of a cone as well as an inverted pyramid.)

[0079] In at least one embodiment, the mobile leaflet layer and the immediately outward structure for the full axial length of the leaflet (cusp wall layer, frame, or other) are a single continuous piece of material.

[0080] In at least one embodiment, at the base of each cusp (that is, at the most proximal extent of the leaflet), the circumferential extent of attachment of the membrane to the frame is less than the circumferential extent of attachment of the membrane to the frame at the distal end of the cusp. In addition, at the base of each cusp, the circumferential extent of transverse (that is, on a line or on the plane of a circumferential single-plane curve of folding that is generally perpendicular to the flow axis of the valve) folding of the membrane to the frame is less than the circumferential extent of transverse folding at the distal end of the cusp.

[0081] At least one embodiment, a prosthetic valve described herein comprises an integrated cusp and leaflet structure wherein the apposing sides of the cusp are joined at one or more axially oriented seams. In at least one embodiment, all folds and seams are located on line segments.

[0082] At least one embodiment of the one or more present inventions does not include frame elements, such as support members, spanning the interior of the valve luminal to support one or more portions of the membrane sheet. Moreover, at least one embodiment of the one or more present inventions does not include any hardware shaping form inward of or attached to any portion of the mobile leaflet portion of the membrane.

[0083] In addition, at least one embodiment of the one or more present inventions does not utilize attachment of the leaflet layer to the frame along the substantially complete circumferential distance separating the commissures at any point below (more proximal than) the commissure tabs.

[0084] At least one embodiment of the one or more present inventions does not include a transverse fold or reflection of the leaflet layer along the substantially complete circumferential distance separating the commissures at any point below (more proximal than) the commissure tabs.

Nomenclature

[0085] For all embodiments presented herein it is to be understood that a “membrane” includes suitable materials for forming the cusps and leaflets. Accordingly, with regard to particular material types that may be used to form the membrane sheet, in at least one embodiment the membrane sheet forming the cusp or leaflet portions includes a one-piece, single layer sheet of biocompatible membrane, such as fixed mammalian pericardium tissue or synthetic biocompatible material, such as ePTFE. In at least one embodiment, the membrane sheet is made from a tissue preparation process that yields a leaflet material of suitable strength and durability for use in a prosthetic transcatheter deliverable heart valve. The content of WO 2011/109450A2 published on Sep. 9, 2011, is incorporated herein by reference. Although the membrane sheet is preferably a single piece of material, a membrane sheet formed of a plurality of pieces of material may be used, such as two to fifty or more pieces of material that are connected.

[0086] As used herein “proximal” means situated near or closer to the upstream or flow inlet end of the valve, and “distal” means situated near or closer to the downstream or flow outlet end of the valve. This convention is further applied in the description of the various folded structure elements (membrane sections, edge segments and fold lines) that are termed “proximal” or “distal” if the final position or orientation of said element within the completed folded structure satisfies the above definitions. Likewise, one of said elements is termed, “axial”, “transverse” or “circumferential” to describe its position and orientation in the completed valve.

[0087] As used herein, a “cusp” means that structural portion of a valve related to a single leaflet that encompasses a space closed toward the lower (proximal) direction and open to the upper (distal) direction, formed by the joined and/or continuous structures of the mobile leaflet portion on the radially inner side and the cusp wall portion on the radially outer side. The “cusp” in the present invention is that structure described as having a substantially conical shape.

[0088] As used herein, the “mobile leaflet layer” or “leaflet” means that radially inward portion of the cusp that moves during operation of the valve. For example, when the valve is closing the mobile leaflet layer moves radially inward toward the central axis of the valve lumen. When the valve is opening, the mobile leaflet layer moves radially outward and away from the central axis of the valve lumen.

[0089] As used herein, the “cusp wall layer” means a portion of the cusp that resides radially outward of the mobile leaflet layer. In some embodiments, a portion of the cusp wall layer moves during operation of the valve. In other embodiments, the cusp wall layer remains substantially immobile during operation of the valve.

[0090] As used herein, the “cuff wall layer” means a portion of the folded membrane structure that resides radially outward of both the cusp wall layer and the mobile leaflet layer, and where present, is radially closest to the frame of the three layers comprising the mobile leaflet layer, the cusp wall layer, and the cuff wall layer. The cuff wall layer remains substantially immobile during operation of the valve.

[0091] A “frame” as used herein means a substantially tubular member that holds a plurality of cusps and/or leaflets. By way of example, the frame may be a wire lattice or a lattice cut from a single tubular piece of metal alloy, that is both collapsible and expandable.

[0092] A “valve” as used herein means a frame with a plurality of cusps and/or leaflets attached thereto. In the present invention each of said leaflets is an integral part of a folded membrane cusp structure. If a frame is used that is a metal lattice that is both collapsible and expandable, such a construct may be delivered through a catheter percutaneously to a target site within a patient, such as the aortic valve.

[0093] As used herein, “cone” or “conical” means resembling a cone or portion thereof at some point in the practical use of the structure.

[0094] As used herein “substantially conical” means resembling a cone or a portion thereof at some point in the practical use of the structure with the specific property that the transverse (that is, on a plane of section generally perpendicular to the axis of flow of the valve) cross-sectional perimeter or area of said structure in the operationally closed position decreases monotonically moving from the level of the leaflet apposition to the proximal end of the valve.

[0095] As used herein, “two or more leaflets,” “two or more valve leaflets,” “a plurality of leaflets” or a similar term means two, three, four, or more valve leaflets. Accordingly, “a valve with two or more leaflets” includes a valve with two leaflets, a valve with three leaflets, a valve with four leaflets, and a valve with more than four leaflets.

[0096] As used herein, a “folding” means the partition of a flat sheet section of material along a sharp line of folding or crease into subsections each lying on separate planes, but without interruption of material continuity.

[0097] As used herein, a “complete folding” means folding (as above) wherein the angular change of the planar axis at the line of folding is approximately 180 degrees, such that the subsections lie on approximately parallel planes and the subsections are in approximate overlying contact with each other at least at some point.

[0098] As used herein, a “cuff” means that portion of a valve structure that lies radially outward of the cusp wall portion that in some part circumferentially encompasses at least a portion of the cusp structure and acts to limit flow that may pass retrograde around the cusp.

[0099] As used herein, “commissure” means the site of union or junction between adjacent cusps and/or leaflets, and by extension, collectively those portions of the adjacent integrated cusp and leaflet structures that are coincident at the union or junction in the completed valve structure.

[0100] As used herein, an “integrated cusp and leaflet folded structure” means a membrane folded in accordance with one of the patterns described herein.

Folded Valve Integrated Cusp and Leaflet—Folding Pattern No. 1

[0101] Referring generally to FIGS. 1A-7K, each cusp embodiment of an integrated cusp and leaflet structure described herein is a substantially flattened cone collapsed along an axis substantially perpendicular to its longitudinal axis. In one or more embodiments, the integrated cusp and leaflet structure, when being formed from a piece of membrane, is readily realized by folding a flat sheet of membrane from a closed polygon pattern. The pattern folding results in apposing seam lines aligned along their axial length. These are joined to close the cusp in the general shape of a cone with the joined seam forming the “spine” along which the cusp meets the inner aspect of the tubular frame. It can be seen that, when formed of a dry sheet membrane, the pattern results initially in a cusp shape that is an inverted pyramid with a rhomboid base that, with a flexible, pliable membrane, is congruent to a substantially conical shape. On relaxation of the folds in practical use a substantially conical cusp is realized wherein the inner mobile operating portions of the leaflet are continuous with the outer portion that forms the integral wall of the cusp sinus or pocket.

[0102] Referring now to FIG. 1A, a plan view of a rectangular flat sheet membrane template 100 is shown for the formation of a single-piece folded valve integrated cusp and leaflet. The plan view is shown with a view of that leaflet surface that faces radially inward once folded and mounted within a frame. Reference is also made to FIG. 1G, wherein a schematic of a valve in distal axial view is shown, and wherein three cusps with integral leaflets are shown within the frame that collectively form the valve. As described and illustrated in the present application, alternate polygons and other closed shapes may be employed with alternate folding patterns to generate alternate shapes and functional features of the valve cusp and leaflet, and complete valve.

[0103] Referring again to FIG. 1A, and in accordance with at least one embodiment of the one or more present inventions, dotted lines 101, 116, 117, 126 and 127 represent the position of folds or creases applied to a piece of membrane to form a leaflet structure 130. More particularly, folding at lines 116, 126 and 101 is initiated inward (with convexity of the surface disposed radially inward toward the central axis of the valve lumen) while folds 117 and 127 are folded initially outward (with convexity of surface disposed radially outward away from the central axis of the valve lumen). Since folding causes re-orientation of the various sections of the sheet template in relation to each other and to the valve geometry, final orientation of the fold lines within the structure on mounting and operation of the leaflets will not necessarily retain the same orientations as on initiation of the folds. The “inward” and “outward” conventions by this definition will be followed throughout the descriptions of the various folded geometries presented herein.

[0104] Referring again to FIG. 1A, a line of division by cutting is indicated at 102. Cutting at 102 results in opposing edges 115 and 125 that will be separated by folding. The other free edges of the structure are labeled as their position and orientation changes through the folding steps. Fold 101 defines the central axis of symmetry of the leaflet pattern, with the concave side of fold 101 facing radially outward toward the frame and away from the central axis of the valve lumen. Fold 101 assists in the maintenance of axial symmetry of the folded construct, but is not necessary to leaflet function and is not retained in the final operational form of the valve. (See FIG. 7A.)

[0105] Referring now to FIG. 1B, an oblique axial top (distal) perspective view of a substantially completed folded leaflet structure 130 is shown. (Three completed folded cusp and leaflet structures 130 are typically mounted to a frame to form an operating heart valve.)

[0106] The view of FIG. 1B is directed downward (proximally) and radially outward, with such view illustrating a substantially completed folded leaflet and cusp structure 130 that depicts the reoriented segments and sections of FIG. 1A after execution of the template foldings. Segments 111 and 121 form the left and right halves of the distal free edge of the mobile operating portion of the leaflet. Inward folding at 116 and 126 forms a second layer of membrane outward of the first, with segments 112 and 122 forming the distal free margin of the outer wall of the integrated cusp. In radially flatted form of the integrated cusp and leaflet structure (that is, approximating the open operating position of the leaflet), the segment 111 will appose to 112, and 121 will appose to 122.

[0107] The left cusp wall section 161 is bounded by folds 116 and 117 and edge segment 112. The right cusp wall section 171 is bounded by folds 126 and 127 and edge segment 122.

[0108] The left cuff wall section 118 is bounded by fold 117 and edge segments 113, 114 and 115. The right cuff wall section 128 is bounded by fold 127 and edge segments 123, 124 and 125. Inward folding at 117 and 127 cause these cuff wall sections 118 and 128 to position outward of the cusp wall sections 161 and 171, respectively. In radially flatted form of the completed folded structure (again, approximating the open operating position of the leaflet), the edge segment 113 will appose to 112, and edge segment 123 will appose to 122.

Folded Valve Folding Sequence

[0109] Referring now to FIGS. 1C and 1D, oblique axial top (distal) perspective views of a partially completed folded leaflet and cusp are shown. The views provided by FIGS. 1C and 1D are directed downward (proximally) and radially outward, with such views depicting the reoriented segments and sections of FIG. 1A after partial execution of the template foldings.

[0110] FIG. 1C shows a perspective view of the inner aspect of the template 100 after initiation of the foldings and cutting at 102 resulting in left and right cuff wall sections 118 and 128, respectively. The cut free edges 115 and 125 are separated along with the left and right cuff wall sections 118 and 128 by outward folding at 117 and 127, respectively. Completed folding at 117 and 127 results in the cuff wall sections 118 and 128, respectively. Distally situated (with respect to the blood flow direction) edge segments 113 and 123 of the cuff wall sections 118 and 128, as well as proximally situated edge segments 115 and 125 of the cuff wall sections 118 and 128, are positioned transverse, and in at least one embodiment, substantially perpendicular, to the central axis of the valve.

[0111] FIG. 1D shows the cusp and leaflet structure 120 with the folds 116, 126, 117 and 127 at an intermediate stage of completion. Triangular left and right mobile leaflet sections 119 and 129 respectively are bounded by folds 101 and 116 and free edge segment 111 on the left, and folds 101 and 126 and free edge segment 121 on the right. Folds 117 and 127 are then brought into apposition on the outward aspect of the integrated cusp and leaflet along a seam line 132 where the folds will be joined and attached to a frame to close the shape of the single-piece continuous conical integrated cusp and leaflet.

[0112] Referring now to FIGS. 1E and 1F, oblique axial top (distal) perspective views of a substantially completed folded cusp and leaflet are shown. The views provided by FIGS. 1E and 1F are directed downward (proximally) and radially outward, with such views depicting the reoriented segments and sections of FIG. 1A after execution of the template foldings.

[0113] FIG. 1E shows the cusp and leaflet folding substantially completed forming the structure 130 with the seam 132 formed by the apposition of folds 117 and 127, thus forming a generally conical cusp and sinus space 131. The triangular corners formed at the distal ends of folds 116 and 126 are apposed to and attached to the cuff wall sections 118 and 128, respectively. Between adjacent cusp and leaflet structures in a multi-leaflet valve, the folded corners form the junction joining the adjacent free edges (121 of leaflet A to 111 of leaflet B, for example) of the mobile leaflet portions. When further attached to the circumferential valve frame, these corners tether the free edges of the mobile leaflet portions to the circumferential inner boundary of the generally cylindrical valve frame, thus forming valve leaflet commissures at each similar join.

[0114] Referring now to FIG. 1F, a structure similar to that of FIG. 1E is depicted, but with the cuff wall sections 118B and 128B reduced in circumferential extent from that of leaflet structure 130 shown in FIG. 1E. More particularly, depending on the clinical application of the valve, a fully circumferential cuff wall may be unnecessary, and a valve with a limited cuff wall with less tissue membrane mass may offer functional advantages. Alternatively, an additional piece of membrane may be placed circumferentially around the outer abluminal surface of the valve frame to act as a sealing cuff to form a barrier against valvular regurgitation.

[0115] Referring again to FIG. 1E, the apex 133 (proximal tip) of the conical cusp and leaflet forms the lower (proximal) end of the seam 132. In at least one embodiment, the apex 133 is also attached to the circumferential boundary of the valve and valve frame.

[0116] Referring now to FIG. 1G, for ease of reference the structure of FIG. 1E is again shown in FIG. 1G at the top of the page, along with a top (distal) cross-section view of the distal end of a three-leaflet valve in the closed operating position. The three cusps with leaflets are shown residing within a lattice frame in order to indicate the configuration of elements between the folded integrated cusp and leaflet structure 130 and its disposition within a three-leaflet frame-mounted valve. Suture attachments are omitted for clarity.

[0117] For each folded integrated cusp and leaflet structure, the outer axial seam 132 is aligned with one or more frame members 141 in a manner to permit the attachment of the folds 117 to 127, and to the coincident frame member by the same attachment, for example, by a single knot or line of suture. Advantageously for this purpose, the frame may preferentially contain axially oriented members that align to the seam 132 for part or all of the full axial extent of the valve. Further, said axially oriented members may advantageously contain holes or notches for securing and tying suture.

[0118] In FIG. 1G at point A, an illustrated loop symbolizing a suture knot is shown to demonstrate that a single knot may advantageously pass through or engage the frame member and the six layers; that is, the mobile leaflet section, the cusp wall section, and the cuff wall section of each adjoining cusp and leaflet structure that are coincident at this site of the commissure.

[0119] Referring still to FIG. 1G, it can be seen that the folded integrated cusp and leaflet structure, when mounted within the lattice frame and placed in the closed operating position, manifests the following configurations: (1) the left leaflet free edge segment 111 is in each case apposed to the right leaflet free edge segment 121 of the adjacent leaflet; (2) the portions of the leaflets just proximal to the free edges, thus, are also apposed to form the contact seal that enables effective closing operation, thereby preventing valvular regurgitation; and (3) the distal edges 112 and 122 of the cusp wall sections are apposed to the distal edges of the cuff wall sections 113 and 123, respectively.

Folded Valve Pattern Variation No. 2

[0120] Referring now to FIG. 2, and in accordance with at least one embodiment, a plan view of a flat sheet membrane template 200 that is polygonal rather than rectangular is shown. Template 200 contains folds 201, 216, 226, 217 and 227 that correspond to folds 101, 116, 126, 117 and 127, respectively, and are disposed in like manner in folding execution, as are the segments enumerated. The folding pattern is designed to form a longer cone of the same diameter, which achieves a more distally disposed central point of valve leaflet coaptation, the mechanics of which are more tolerant of pressure loads. The pattern dimensions may be altered to suit the particular clinical application of the valve. The template examples disclosed herein are for enablement purposes and shall not be interpreted as limiting the scope of the claims. The example is shown for a cusp cone wall disposed at about a 60 degree angle to the horizontal (short axis) of the generally cylindrical valve geometry, whereas that angle for the rectangular pattern of FIGS. 1A-1G was about 45 degrees.

Folded Valve Pattern Variation No. 3

[0121] Referring now to FIG. 3, and in accordance with at least one embodiment, a plan view of template 300 is shown for a flat sheet membrane that contains the pattern 200 of FIG. 2 with added sections that extend the distal contour of the structure when completed in folding. More particularly, the free edge of the mobile leaflet section is extended distally with a section having a polygonal or curved free edge in order to increase the contacting area of leaflet apposition in valve closing operation. Additionally, the distal contour of the cusp wall sections and cuff wall sections 318 and 328 are extended by “tab” sections 318T and 328T, respectively. These added “tab” extensions allow for increased area by which to mount the outer wall of the cusp and leaflet assembly to the frame and for elevating the cuff wall “above” (more distal to) the plane of leaflet apposition, thereby also increasing the effective volume of the cusp in closing operation. These “tab” extensions, being distally disposed after completion of folding and initial mounting within the lattice frame, or a distal portion of them may optionally be folded radially outward along 312-313 and 322-323, for example, to wrap around the distal edge of the frame such that the “tab” extension areas 318T and 328T lie on the outer, abluminal aspect of the frame where, when attached to the frame, they potentially increase the strength of the cusp attachment.

[0122] Referring still to FIG. 3, template 300 contains folds 301, 316, 326, 317 and 327 that correspond to folds 101, 116, 126, 117 and 127, respectively, and are disposed in like manner in folding execution, as are the edge segments similarly enumerated. In addition to the tab features discussed in the preceding paragraph, as with template 200, template 300 is designed to form a longer cone of the same diameter, which achieves a more distally disposed central point of valve leaflet coaptation. Again, the pattern dimensions may be altered to suit the particular clinical application of the valve. The example is shown for a cusp cone wall disposed at about a 60 degree angle to the horizontal (short axis) of the generally cylindrical valve geometry.

Folded Valve Pattern Variation No. 4

[0123] Referring now to FIG. 4, and in accordance with at least one embodiment, a plan view of pattern 400 is shown for a flat sheet membrane similar to pattern 300, except that the extension “tab” sections 412T and 422T are distal extensions of the cusp wall sections only. This limitation reduces the double layer of membrane extension at the distal end of the completely folded integrated cusp and leaflet structure to a single layer, thereby reducing the mass of membrane in the heart valve which might otherwise disadvantageously limit the efficiency of collapsing and compressing the valve for use in the percutaneous/transcatheter delivery application.

[0124] In addition, at the lower (proximal) apex 433 of the cusp cone pattern the lower (proximal) extent of the cuff wall sections 418 and 428 is limited so as to “expose” the apex of the cone in the pattern. This feature allows, on the completely folded integrated cusp and leaflet structure, the transverse, radially outward folding of the tip of the cone-shaped cusp at line 403 between points U and V. (See FIGS. 7.) The folding of the apex reduces the overall axial length of the cusp and leaflet structure, allowing for increased cusp/sinus volume for a given valve diameter and frame length.

[0125] The template 400 contains folds 401, 416, 426, 417 and 427 that correspond to folds 101, 116, 126, 117 and 127, respectively, and are disposed in like manner in folding execution, as are the edge segments similarly enumerated. Similar to templates 200 and 300 described above, template 400 dimensions may be altered to suit the particular clinical application of the valve. The example is shown for a cusp cone wall disposed at about a 60 degree angle to the horizontal (short axis) of the generally cylindrical valve geometry.

Folded Valve Pattern Variation No. 5

[0126] Referring now to FIGS. 5A-5F, yet another embodiment of a template pattern is illustrated. Referring specifically now to FIG. 5A, a plan view of template 500 is shown for a flat sheet membrane. The template 500 contains folds 501, 516, 526, 517 and 527 that correspond to folds 101, 116, 126, 117 and 127, respectively, and are disposed in like manner in folding execution, as are the edge segments similarly enumerated.

[0127] Template 500 illustrates a flat sheet membrane that is basically rectangular and is similar to the upper (distal) portion of template 100 of FIGS. 1A-1G, except that (a) the distal extension areas 512T and 522T are added at the left and right margins of the template 500, and (b) the lower quadrants forming the cuff wall sections of the template 100 are truncated in template 500 to narrow cuff wall sections 518 and 528, the extent of which is defined by the length of cut 502. These limited interior cuff sections are still used for frame attachment along the central seam 532 of the cusp and leaflet cone, and the distal extension sections 512T and 522T are still used for attachment of the outer cusp wall to the distal edge of the frame.

[0128] Referring still to FIGS. 5A-5F, corner folds 505 and 506 are now described. For template 500, after folds 516 and 526 are executed by complete folding, segments 512 and 522 are apposed and aligned to segments 511 and 521, respectively, and overlapping layers (mobile leaflet layer and cusp wall layer) form triangular corner sections at 562 and 572. Radially outward folding of these corner sections at 505 and 506 define the axial extent of the leaflet commissures such that joining the corner sections of adjacent leaflet structures along corner folds 505 and 506 causes the leaflet apposition to be at least the length of 505 in axial extent at the radial margin of the leaflet. (See FIG. 9E that illustrates an embodiment of a valve comprising a frame 920 with a plurality of integral cusp and leaflet structures 730 attached to the frame, wherein the structures 730 include corner sections 762 and 772 corresponding to the corner sections 562 and 572 of template 500.) Additionally, these double-layer triangular corner sections 562 and 572 are used for attachment of the commissures to the frame. The stent frame may optionally contain a slot at this point of attachment through which this triangular “tab” section may be inserted and attached on the abluminal surface of the frame. (Again, see FIG. 9E.)

[0129] With specific reference now to FIG. 5B, a perspective view of the inner aspect (that is, a view directed radially outward) of an initially folded structure 510 folded according to template 500 is shown. The central folding along 501 is initiated after cut 502 is executed as shown. Foldings along 501, 516, and 526 are depicted as initiated radially inward (out of the page) and foldings along 517 and 527 are depicted as initiated radially outward (into the page).

[0130] FIG. 5C shows a steeply oblique perspective view of the folded integrated cusp and leaflet 520 at an intermediate stage of completion of the foldings. The view is directed from the central axis outward and obliquely downward into the cusp space showing the formation of the outer wall of the structure, that is, the cusp wall layer of the subject cusp. Folding along 517 and 527 acts to position the extension sections 518 and 528 outward of the cusp wall sections 561 and 571, respectively. Completion of folding then will position folds 517 and 527 in an axially aligned orientation in apposition to each other along their length. Folding along 516 and 526 acts to position the cusp wall sections 561 and 571 outward of the mobile leaflet sections 519 and 529, respectively. Completion of folding, which radially collapses the folded flattened structure, positions the cusp wall sections 561 and 571 in apposition to the mobile leaflet sections 519 and 529, respectively. In the final folded configuration the structure embodies the integrated cusp and leaflet in the open operating position.

[0131] In addition, completed folding at 516 and 526 also forms triangular two-layer sections, 562 and 572, respectively, that are designated as “commissure tabs”. These commissure tabs are bounded by the corner folds 505 and 506, folds 516 and 526, and the free edges 511 and 521 of the mobile leaflet sections 519 and 529, respectively. With further reference to FIGS. 5D and 5E, these commissure tabs will be folded at 505 and 506 so as to position both layers of the tabs outward of the cusp wall sections 561 and 571, respectively, with the folds 505 and 506 oriented parallel to the central axis of the valve. With regard to a multi-leaflet valve, when the cusp and leaflet structure is mounted within the frame, this folded commissure tab is aligned along fold 505 in apposition to fold 506 of an adjacent complementary commissure tab of an adjacent integrated cusp and leaflet structure. Thus mounted, the commissure tabs join the mobile leaflet layers and the cusp wall layers of adjacent folded cusp and leaflet structures along a line coincident to both 505 and 506 that forms a common seam for attachment, such as by suturing of the commissure tabs to each other and to the frame forming the circumferential margin of the membrane portion of the folded cusp and leaflet structure.

[0132] FIG. 5D shows a plan view of the inner (luminal) aspect of the folded integrated cusp and leaflet structure 530 of template pattern 500. Structure 530 is depicted in a completed state of folding, excepting that the commissure tabs 562 and 572 are not yet folded outward along fold lines 505 and 506, respectively. The radially flattened form shown gives the general configuration and orientation of the membrane segments and sections for the open operating position of the valve cusp and leaflet.

[0133] Still referring to FIG. 5D, at the uppermost (distal) portion of the cusp wall layer, the extension tabs 512T and 522T are projected above (or distal to) the lines 512 and 522 (shown in FIGS. 5A and 5B), respectively, that lie in apposition and alignment to the free edges 511 and 521, respectively, of the mobile leaflet layer. A portion or all of these tabs 512T and 522T may be optionally folded outward along 512 and 522, respectively, around the distal edge of the frame to lie upon the outer (abluminal) surface of the frame where they may be attached to both the frame and to the cusp wall sections (where the cusp wall sections are apposed to the inner surface of the frame) through the interstices of the frame. This optional configuration provides for increased strength of attachment for bearing downward (proximally directed) operational loads associated with the valve closing.

[0134] Completing the folding associated with template pattern 500 places folds 517 and 527 into axial alignment. Once in axial alignment, apposing folds 517 and 527 are joined along their axial length to form the seam 532 that closes the generally conical cusp structure with the extension sections 518 and 528 situated outward of the cusp wall sections 561 and 571, respectively. The cusp wall sections 561 and 571 are thus disposed outward of the mobile leaflet sections 519 and 529, respectively, with the cusp wall sections axially and circumferentially apposed to the inner surfaces of the generally cylindrical frame. Advantageously, for each valve cusp and leaflet to be mounted within, the frame may contain an element or elements that are axially oriented and span a significant portion of the axial length of the frame, so as to align with the seam 532 for attachment, such as by suturing to the frame.

[0135] Referring now to FIG. 5E, a partial detail perspective view is shown of the commissure tab 572 configuration of the completely folded integrated cusp and leaflet structure 530, indicating radially outward folding of the commissure tab 572 along fold line 506.

[0136] With reference now to FIG. 5F, a perspective view is shown of the outer (abluminal) aspect of the completely folded cusp and leaflet structure 530 (except that the triangular commissure tabs are not yet folded) of template 500 in substantially flattened form. This view is complementary to FIG. 5D that shows the inner aspect of the same structure 530. The central seam 532 is seen on the outer face of the cusp wall sections 561 and 571 and is depicted for purposes of illustration as partly separated with the extension sections 518 and 528 incompletely flattened and folds 517 and 527 in close, but not in the complete apposition and alignment that will form the final seam line 532 for attachment to the axially oriented frame members. The slight separation depicted between folds 517 and 527 exposes the centerpoint of the mobile leaflet free edge where the mobile leaflet free edge segments 511 and 521 meet as depicted behind the cusp wall sections 561 and 571, respectively, in this view.

Folded Valve Pattern Variation No. 6

[0137] In accordance with at least one embodiment, FIG. 6 shows a plan view of another template 600 that is similar to template 500 except that the cusp cone wall angle α exceeds the 45 degrees of the generally rectangular template 500, and that the mobile leaflet sections are extended by a polygonal or curved extension section 604 of the free edge.

[0138] The change in cusp cone wall angle α also results in changes in the angle relating the lower (proximal) margins of the template and fold lines 617 and 627 to the center line of the template in order that when folding is completely executed, the fold lines 617 and 627 and the seam between them will be parallel to the central axis of the assembled valve. Likewise, the further geometry of the cusp cone wall angle will result in fold lines (optional) 613 and 623 and the long axes of extension tabs 612T and 622T being parallel to the transverse axis of the assembled valve.

[0139] The template 600 contains folds 601, 616, 626, 617, 627, optional folds 612 and 622, corner folds 605 and 606, and cut line 602 that correspond to folds 501, 516, 526, 517, 527, optional folds 512 and 522, corner folds 505 and 506, and cut line 502, respectively, of template pattern 500 and are disposed in like manner in folding execution, as are the template sections and edge segments similarly enumerated.

Folded Valve Pattern Variation No. 7

[0140] Referring now to FIGS. 7A-7F, still yet another embodiment of a template pattern is illustrated. Referring specifically now to FIG. 7A, a plan view of another template 700 is shown that is similar to template 600, but with a section of the lower (proximal) midline portion of the template cut away so as to expose the apex 733 of the triangular sections that, when folded, will form the apex of the cone-shaped cusp. Effectively, the midline portions of the extension sections 718 and 728 are removed in relation to template 600 to an extent determined by the desired length of the line segment U-V, which in turn determines the extent to which the apex of the cone-shaped cusp may be truncated by folding at U-V.

[0141] After the cusp and leaflet cone is formed by folding, the apex is folded radially outward at line U-V (703) to truncate the cone to reduce the overall length of the cusp and leaflet structure, allowing for increased cusp/sinus volume for a given valve diameter and frame length.

[0142] The template 700 contains folds 701, 716, 726, 717, 727, optional folds 712 and 722, and corner folds 705 and 706, that correspond to folds 601, 616, 626, 617, 627, optional folds 612 and 622, and corner folds 605 and 606, respectively, of template 600 and are disposed in like manner in folding execution, as are the template sections and edge segments similarly enumerated.

[0143] FIG. 7B shows a perspective view of the inner (luminal) aspect of the initially folded cusp and leaflet structure 710 of template 700 after initiation of the principal folds 716, 726, 717, 727 and 701. Inward folding along 701 assists in aligning the left and right sections of the structure, but is not necessary to the formation of the integrated cusp and leaflet folded structure or to the operation of the valve. The disposition of the folds that converge at the apex 733 of the cusp can be appreciated as later forming an overlapping two-layer triangular apex as the cusp wall sections 761 and 771 are folded outward along lines 716 and 726, respectively, so as to position the cusp wall sections 761 and 771 outward of, and in apposition to, the mobile leaflet sections 719 and 729, respectively.

[0144] FIG. 7C shows a steeply oblique perspective view of the folded integrated cusp and leaflet 720 at an intermediate stage of completion of the foldings. The view is directed from the central axis outward and obliquely downward into the cusp space showing the formation of the outer wall of the structure. Folding along 717 and 727 acts to position the extension sections 718 and 728 outward of the cusp wall sections 761 and 771, respectively. Completion of folding then will position folds 717 and 727 in an axially aligned orientation in apposition to each other along their length. Folding along 716 and 726 acts to position the cusp wall sections 761 and 771 outward of the mobile leaflet sections 719 and 729, respectively. Completion of folding, which radially collapses the folded flattened structure, positions the cusp wall sections 761 and 771 in apposition to the mobile leaflet sections 719 and 729, respectively. In the final folded configuration, the structure embodies the integrated cusp and leaflet in the open operating position.

[0145] With reference to FIG. 7D, completed folding at 716 and 726 also forms triangular two-layer sections, 762 and 772, respectively, that are designated as “commissure tabs.” These commissure tabs are bounded by the corner folds 705 and 706, folds 716 and 726, and the free edges 711 and 721 of the mobile leaflet sections 719 and 729, respectively. With further reference to FIGS. 7D and 7E, these commissure tabs will be folded at 705 and 706 so as to position both layers of the tabs outward of the cusp wall sections 761 and 771, respectively, with the folds 705 and 706 oriented parallel to the central axis of the valve. When the integrated cusp and leaflet structure is mounted within the frame, this folded commissure tab is aligned along fold 705 in apposition to fold 706 of an adjacent complementary commissure tab of an adjacent integrated cusp and leaflet structure of a multi-leaflet valve. Thus mounted, the commissure tabs join the mobile leaflet layers and the cusp wall layers of adjacent folded cusp and leaflet structures along a line coincident to both 705 and 706 that forms a common seam for attachment, such as by suturing of the commissure tabs to each other and to the frame forming the circumferential margin of the membrane portion of the folded cusp and leaflet strucutre.

[0146] FIG. 7D shows a perspective view of the inner (luminal) aspect of the partially folded integrated cusp and valve structure 720 of template 700. Integrated cusp and leaflet structure 720 is depicted in nearly completed state of folding, except that the commissure tabs 762 and 772, as well as the cusp apex 733 are not yet folded outward along fold lines 705, 706 and 703, respectively, and that the axial seam 732 is not yet formed by the apposition of the folds 717 and 727.

[0147] At the uppermost (distal) portion of the cusp wall layer, the extension tabs 712T and 722T are projected above (or distal to) the lines 712 and 722 (shown in FIGS. 7A and 7B). All or a portion of these tabs 712T and 722T may be optionally folded outward along 712 and 722, respectively, around the distal edge of the frame to lie upon the outer (abluminal) surface of the frame where they may be attached to both the frame and to the cusp wall sections (apposed to the inner surface of the frame) through the interstices of the frame. This optional configuration provides for increased strength of attachment for bearing downward (proximally directed) operational loads associated with the valve closing.

[0148] Completing the folding associated with template pattern 700 places folds 717 and 727 into axial alignment. Once in axial alignment, apposing folds 717 and 727 are joined along their axial length to form the seam 732 that closes the generally conical cusp structure with the extension sections 718 and 728 situated outward of the cusp wall sections 761 and 771, respectively. The cusp wall sections 761 and 771 then are disposed outward of the mobile leaflet sections 719 and 729, respectively, with the cusp wall sections axially and circumferentially apposed to the inner surfaces of the generally cylindrical frame. Advantageously, for each integrated cusp and folded leaflet structure to be mounted within, the frame may contain an element or elements that are axially oriented and span a significant portion of the axial length of the frame, so as to align with the seam 732 for attachment as by suturing to the frame.

[0149] FIG. 7E shows a shallow oblique top perspective view of the outer (abluminal) aspect of the partially folded cusp and leaflet structure 720 of template 700 (except that the triangular commissure tabs 762 and 772 and apex 733 are not yet folded and that the axial seam 732 is not yet joined). This view is complementary to FIG. 7D that shows the inner aspect of the same structure 720. The central seam 732 will be formed on the outer face of the cusp wall sections 761 and 771 as folds 717 and 727 are brought together into apposition along the midline, with the extension sections 718 and 728 thus also aligned. The outward (abluminal) face of the mobile leaflet sections 719 and 729 are shown between the yet separated folds 717 and 727 before closure of the generally conical cusp along the outer seam 732.

[0150] FIG. 7F shows a plan view of the inner (luminal) aspect of the folded integrated cusp and leaflet structure 720 of template pattern 700. Structure 720 is depicted in a completed state of folding, excepting that the commissure tabs 762 and 772 are not yet folded outward along fold lines 705 and 706, respectively. In addition, the apex 733 is not folded outward. The radially flattened form shown gives the general configuration and orientation of the membrane line segments and areal sections for the open operating position of the valve cusp and leaflet.

[0151] At the uppermost (distal) portion of the cusp wall layer, the extension tabs 712T and 722T are projected above (distal to) the lines 712 and 722 (shown in FIGS. 7A, 7B and 7G), respectively, below (proximal to) which the cusp wall sections 761 and 771 lie in radial apposition to the mobile leaflet sections 719 and 729, respectively, of the mobile leaflet layer. These tabs 712T and 722T may be optionally folded outward along 712 and 722, respectively, around the distal edge of the frame to lie upon the outer (abluminal) surface of the frame where they may be attached to both the frame and to the cusp wall sections (apposed to the inner surface of the frame) through the interstices of the frame. This optional configuration provides for increased strength of attachment for bearing downward (proximally directed) loads of valve closing.

[0152] Folding of the template positions folds 717 and 727 into axial alignment, joined along their axial length to form the seam that closes the generally conical cusp structure with the extension sections 718 and 728 reflected outward of the cusp wall sections 761 and 771, respectively. The cusp wall sections 761 and 771 then are disposed outward of the mobile leaflet sections 719 and 729, respectively, with the cusp wall sections 761 and 771 axially and circumferentially apposed to the inner surfaces of the generally cylindrical frame. Advantageously, for each valve cusp and leaflet folded structure to be mounted within, the frame may contain an element or elements that are axially oriented and span a significant portion of the axial length of the frame, so as to align with the seam 732 for attachment as by suturing to the frame.

[0153] FIG. 7G shows a perspective view of the outer (abluminal) aspect of the completely folded cusp and leaflet structure 720 (except that the triangular commissure tabs 762 and 772 and apex 733 are not yet folded) of template 700, in nearly flattened form. This view is complementary to FIG. 7F that shows the inner aspect of the same structure 720. The central seam 732 is seen on the outer face of the cusp wall sections 761 and 771 and is depicted for purposes of illustration as minimally separated with the extension sections 718 and 728 incompletely flattened and folds 717 and 727 in effectively complete apposition and alignment that forms the final seam line 732 for attachment to the axially oriented frame members. The slight separation depicted between folds 717 and 727 exposes the centerpoint between the mobile leaflet free edge segments 711 and 721 depicted behind the cusp wall sections 761 and 771, respectively, in this view.

[0154] FIG. 7H shows a plan view of the inner aspect of the completely folded integrated cusp and leaflet structure 730 of template 700. This view is substantially that of FIG. 7F except that the triangular commissure tabs 762 and 772 are folded radially outward of the cusp wall sections 761 and 771 along corner folds 705 and 706, respectively. Additionally, the apex (most proximal) portion of the cone-shaped cusp is folded radially outward along the fold line 703 (between points U and V) to the position radially outward of the joined extension sections 718 and 728 such that the apex point 733 then lies upon the seam line 732.

[0155] FIG. 7I shows a plan view of the radially outer aspect of the completely folded integrated cusp and leaflet structure 730 of template 700. The outwardly folded position of the triangular commissure tabs 762 and 772 can be seen so that they lie in apposition to the outer surface of the cusp wall sections 761 and 771, respectively. While they may attached in this position to the underlying cusp wall layer and to the frame, alternatively, the commissure tabs 762 and 772 may be positioned to point radially outward (out of the page in this view) to pass through a slot or space in the frame to be secured and attached to the outer (abluminal) surface of the frame.

[0156] Additionally, the apex (most proximal) portion of the cone-shaped cusp is folded radially outward along the fold line 703 (between points U and V) to the position radially outward of the joined extension sections 718 and 728 such that the apex point 733 then lies upon the seam line 732.

[0157] The apex portion of the cone-shaped cusp thus configured is to be attached in this position as by suturing and may be similarly attached into this position in the act of attaching or suturing this portion of the folded cusp and leaflet structure to the frame.

[0158] FIG. 7J shows an oblique top perspective view of the completely folded and formed cusp and leaflet structure 730 with the view directed radially outward and downward (proximal). The cusp and leaflet structure is shown with the free edge of the mobile leaflet layer in the inward central position corresponding to the substantially closed operating position of the valve leaflet.

[0159] The commissure tabs 762 and 772 are depicted in radially aligned positions directed outward as would be required for passing them through slots or spaces in a suitably designed frame.

[0160] FIG. 7K shows a top perspective view of the single-piece completely folded and formed cusp and leaflet structure 730 with the view directed downward (proximal) into the cusp space. The cusp and leaflet structure is shown with the free edge of the mobile leaflet layer sections 719 and 729 in the intermediate inward position corresponding to the partially closed operating position of the valve leaflet.

[0161] The membrane structure is depicted with the free edges in a relaxed state corresponding to the typical behavior of tissue membranes when hydrated as when implanted in the body.

[0162] The commissure tabs 762 and 772 are depicted in radially aligned positions directed outward as would be required for passing them through slots or spaces in a suitably designed frame.

Metal Lattice Frame

[0163] FIG. 8A is an oblique top perspective view of a metal lattice frame 910 for mounting three of the single-piece folded integrated cusp and leaflet structures of the ensuing description in order to form a three-leaflet valve. The frame comprises a plurality of strut members 911 and three axially oriented mounting bars 912 each with holes and/or slots for passing suture and/or portions of the folded membrane structure. Each mounting bar 912 is to align with and attach to the axial outer seam of one single-piece completely folded and formed cusp and leaflet structure 730. The diameter D of the open frame, e.g., 19-35 mm naturally defines the deployed and operating diameter of the valve assembly after implantation in the body. The strut members 911 are of specific length and orientation to permit radial collapse and compression of the frame to a small diameter, e.g., 3-7 mm. The mounting bars 912 are near to equally spaced around the circumferential course of the frame and the length L of the arc from the center of the mounting bar 912 to the center of the closest mounting bar 912 is approximately equal to (pi×D)/3. Thus defined, L also defines the transverse circumferential distance between folds 705 and 706, approximating the circumferential extent of the portions of the joined cusp wall sections 761 and 771 extending between 705 and 706 of the folded cusp and leaflet structure of appropriate size when mounted within the frame 910.

[0164] FIG. 8B shows a side perspective view of the frame 910 with the view centered on the axial mounting bar 912. The axial bars are shown with holes and/or slots for passing suture and/or portions of the folded membrane structure to enable secure mounting of the folded cusp and leaflet structure within the frame.

[0165] FIG. 8C shows a side view of the frame of FIG. 8B with a superimposed plan view of the radially outer aspect of the completely folded integrated cusp and leaflet structure as depicted in FIG. 7I. The cusp wall seam 732 is aligned upon the inner surface of the mounting bar of the frame and attached by sutures in this example. (Example suture locations are shown in FIGS. 8C, 9C and 9D shown with an “x”; however, it is to be understood that the locations shown are exemplary and not limiting.) As those skilled in the art will appreciate, means other than sutures for attaching folded integrated cusp and leaflet structure to the frame can be used.

[0166] The commissure tabs 762 and 772 are folded flat against the outer surface of the cusp wall layer along corner folds 705 and 706 for mounting entirely within the frame 910. Each fold 705 then forms an axially oriented seam along its length with the complementary fold 706 of the adjacent folded cusp and leaflet structure 730. (Adjacent complementary commissure tabs omitted for clarity.) Said seam is closed and attached by suture, for example, while also attaching to the radially overlying strut member 911 of the frame 910, and thereby affixes the distal margins of the cusp wall sections 761 and 771 and the mobile leaflet sections (obverse of this view) to the frame 910. The other suture points depicted attach only the cusp wall layer 761+771 to the overlying frame strut members 911. At no point within the interior operating volume of the valve is the mobile leaflet layer 719+729 penetrated by suture. This uninterrupted continuity of the operating leaflet material afforded by the folded design of the integrated cusp and leaflet structure endows the valve and its leaflets with strength, durability and resistance to stress damage at suture holes.

[0167] FIG. 8D shows an oblique axial (top/distal) perspective view of the assembled three-leaflet valve comprising the frame 910 and three identical folded integrated cusp and leaflet structures 730A, 730B and 730C attached within the frame with the view centered on an axial mounting bar 912A. The suture attachments are omitted for clarity. The cusp and leaflet structure 730A nearest in view is seen within the frame 910, with the outer aspect of the seam 732A, cuff wall extension sections 718A and 728A, and cusp wall sections 761A and 771A viewed through the interspaces of the frame 910. The seam 732A is aligned to the overlying axial mounting bar 912A to which it is attached along its length. The inner (luminal) aspect of the seams 732B and 732C and the cusp wall sections 761B, 771B, 761C and 771C of the other two folded cusp and leaflet structures 730B and 730C, respectively are seen on the far side of the view. The adjoined folded edges of the membrane portions of the commissure tabs 772B and 762C are shown in the far view in position opposite to the axial mounting bar 912A in the near view. The radially outward surface of the mobile leaflet sections 719A and 729A of the folded cusp and leaflet structure 730A is shown in the near view. The distal free edges of all three mobile leaflets are shown in the centrally apposed (coapted) position corresponding to the closed operating position of the valve. FIG. 8D also shows in that aspect interior to the cusps, folds 726B of cusp and leaflet structure 730B and 716C of cusp and leaflet structure 730C as they form the lower (proximal) boundary of the valve cusps.

Slotted Lattice Frame

[0168] FIG. 9A shows an oblique axial (top/distal) perspective view of a frame 920 of a design to receive the commissure tabs 762 and 772 through slots 924 in slotted members 923 in order that the tabs are secured and attached to the outer (abluminal) aspect of the frame. This approach to mounting and attaching the commissure tabs enables the loading forces on the leaflet commissures during valve operation to be advantageously distributed upon the frame slotted members 923 along their length rather than upon suture that directly tethers the leaflets, thus greatly reducing the risk of tearing of the material at points of suture penetration. The frame further comprises axial mounting bars 922 for mounting the central seams 732 joining the cusp wall sections 761 and 771 along folds 717 and 727. The frame further comprises a plurality of strut members 921 that otherwise form the metal lattice of the frame.

[0169] Each mounting bar 922 is to align with and attach to the axial outer seam of one single-piece completely folded and formed cusp and leaflet structure 730. The inner diameter D of the open frame, e.g., 19-35 mm naturally defines the deployed and operating diameter of the valve assembly after implantation in the body. The strut members 921 are of specific length and orientation to permit radial collapse and compression of the frame to a small diameter, e.g., 3-7 mm. The mounting bars 922 are near to equally spaced around the inner circumferential course of the frame. The length L of the arc along the inner circumference of the frame from the center of the mounting bar 922 to the center of the closest mounting bar 922 is approximately equal to (pi×D)/3. Thus defined, L also defines the transverse circumferential distance between folds 705 and 706, approximating the circumferential extent of the portions of the joined cusp wall sections 761 and 771 extending between 705 and 706 of the folded cusp and leaflet structure of appropriate size when mounted within the frame 920.

[0170] The axial mounting bars 922 optionally contain holes and/or slots to facilitate suture attachment of the folded integrated cusp and leaflet structures 730. The frame is depicted in FIGS. 9A-9E as having axial mounting bars 922 each with a hole near the proximal end to facilitate suture attachment of the apical (most proximal) portion of the folded cusp and leaflet structure.

[0171] FIG. 9B shows the metal lattice frame of FIG. 9A in the same perspective, but with the view centered on the slotted frame member 923.

[0172] FIG. 9C shows a side perspective view of the frame 920 centered on the axial mounting bar 922 with a superimposed plan view of the outer aspect of the completely folded integrated cusp and leaflet structure 730 (of FIG. 7I) as mounted within the frame 920 to demonstrate the relationships between the two. An example suture pattern for attachment is shown. The cusp wall seam 732 is aligned upon the inner surface of the mounting bar 922 of the frame 920 and attached by sutures in this example.

[0173] The commissure tabs 762 and 772 are to be understood as having been passed through the frame slots 924 from within the central space of the frame to the outer (abluminal) side and folded along 705 and 706, respectively onto the outer surface of the cusp and leaflet structure where they are attached along their common length both to the frame members 923 and, through the interspaces of the frame 920, to the radially underlying outer aspect of the cusp wall sections 761 and 771, respectively. The adjacent cusp and leaflet structures of the three-leaflet valve are not shown for clarity. The joining of adjacent commissure tabs at the slotted members 923 is demonstrated in FIG. 9D.

[0174] At the apical (most proximal) extent of the completely folded integrated cusp and leaflet structure 730, the apical portion folded radially outward along fold 703 is attached to the lower (most proximal) end of the axial mounting bar 922. When present, a hole near the end of the axial mounting bar 922 facilitates suture attachment at this point.

[0175] FIG. 9D shows a side perspective view of the frame 920 centered on the slotted frame member 923AB with a superimposed perspective view of the outer aspect of two circumferentially adjacent completely folded integrated cusp and leaflet structures 730A and 730B (of FIG. 7I) to demonstrate their relationships as mounted within the frame 920. An example suture pattern for attachment is shown. Suture attachment of the commissure folds 705 and 706 at the level of the slot is notably absent. Rather, attachment of the bodies of the commissure tabs 762A and 772B to the outer aspect of the frame at points removed from the free edges and folds of the material avoids suture penetration along the lines of traction in the slot and enhances the resistance of the structure to tearing at such suture attachments. The cusp wall seams 732A and 732B are aligned upon the inner surface of the mounting bars 922A and 922B, respectively of the frame 920 and attached by sutures in this example.

[0176] The commissure tabs 762A and 772B are to be understood as having been passed through the frame slot 924 from within the central space of the frame to the outer (abluminal) side and folded along 705A and 706B, respectively onto the outer surface of the cusp and leaflet structure where they are attached along their common length both to the frame member 923AB and, through the interspaces of the frame 920, to the radially underlying outer aspect of the cusp wall sections 761A and 771B, respectively.

[0177] FIG. 9E shows an oblique axial (top/distal) perspective view of the assembled three-leaflet valve comprising the frame 920 and three identical folded integrated cusp and leaflet structures 730A, 730B and 730C attached principally within the central space of the frame, but with the commissure tabs passed in complementary adjacent left-right pairs, 762A-772B, 762B-772C and 762C-772A, through the slots 924AB, 924BC and 924CA, of slotted frame members 923AB, 923BC, and 923CA, respectively. The view is centered on slotted member 923AB. The suture attachments are omitted for clarity.

[0178] The cusp and leaflet structure 730C farthest in view is seen within the frame 920, with the inner aspect of the seam 732C and cusp wall sections 761C and 771C in the far view. The cuff wall extension sections 718C and 728C are depicted as folded onto the outer aspect of the cusp wall sections 761C and 771C, respectively, but within the central space of the frame 920 and apposed to the inner surface of the frame. The inner (luminal) aspect of the seam 732C is shown aligned to the outwardly overlying axial mounting bar 922C to which it is attached along its length. The outer (abluminal) aspect of the top (most distal) portions of the seams 732A and 732B and the cusp wall sections 761A and 771B, of the other two folded cusp and leaflet structures 730A and 730B are also shown through the interspaces of the frame on either side of the near view.

[0179] The commissure tabs 762A and 772B, aligned and apposed along folds 705A and 706B, respectively are shown centered in the near view in position opposite to the axial mounting bar 922C and cusp wall seam 732C in the far view. The key mounting configuration of the valve commissures to the slotted frame members is here demonstrated. The triangular commissure tabs are formed as a result of the folding of the membrane template along folds 716 and 726, and are comprised of overlapping layers of the cusp wall section and the mobile leaflet section. Thus, with passage of the commissure tabs from within the interior space of the frame through the frame slots, both the cusp wall layer and the mobile leaflet layer are carried together to the outer aspect of the frame where they are attached. In addition, the interior aspect of the commissure folds 706A of cusp and leaflet structure 730A and 705B of cusp and leaflet structure 730B are shown where they mark the segment at which the commissure tabs 772A and 762B are passed through the frame slots 924CA and 924BC of slotted members 923CA and 923BC, respectively, and are tethered thereto.

[0180] The radially outward surface of the mobile leaflet sections 719A, 729A of the folded cusp and leaflet structure 730A and sections 719B, 729B of the folded cusp and leaflet structure 730B are shown on the left and right sides, respectively of the near view. (These labels omitted for clarity.)

[0181] The distal free edges of all three mobile leaflets are shown in the centrally apposed (coapted) position corresponding to the closed operating position of the valve. FIG. 9E also shows in that aspect interior to the cusps, a portion of folds 726A of cusp and leaflet structure 730A and 716B of cusp and leaflet structure 730B as they form the lower (proximal) boundary of the valve cusps.

[0182] The template examples disclosed herein are provided for enablement purposes and shall not be interpreted as limiting the scope of the claims. For example, angular values shown and/or described herein are not to be interpreted as limiting the scope of a claim unless included in a given claim.

[0183] As those skilled in the art will appreciate, circumference length varies with the diameter circumscribed therein. Accordingly, refinements in the valve manufacturing process may address adjusting the length of the leaflet free edge to be slightly less than the edge length of the cusp wall, i.e., less than the circumferential arc length between the commissures. This adjustment depends upon the dimensions of a given valve in production, as well as the dimensions of the given valve's component elements.

[0184] In still other embodiments of the one or more present inventions, the percutaneously deliverable heart valve may include various other configurations by using different variations of the polygon pattern, so as to include, for example, an inner sealing cuff for the valve that is continuous and integral with the leaflet structure itself In yet other embodiments, the percutaneously deliverable heart valve may include different configurations by adjusting the pattern and folding technique, such as the angle of the cone and its surface area, or the extent of apposition between the leaflets may also be specified.

[0185] The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

[0186] The one or more present inventions, in various embodiments, include components, methods, processes, systems and/or apparatus substantially as depicted and described herein, including various embodiments, subcombinations, and subsets thereof. Those of skill in the art will understand how to make and use the present invention after understanding the present disclosure.

[0187] The present invention, in various embodiments, includes providing devices and processes in the absence of items not depicted and/or described herein or in various embodiments hereof, including in the absence of such items as may have been used in previous devices or processes (e.g., for improving performance, achieving ease and/or reducing cost of implementation).

[0188] The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the invention are grouped together in one or more embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate preferred embodiment of the invention.

[0189] Moreover, though the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention (e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure). It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.

Claims

Post-issuance certificates present

The text shown below may not reflect later post-issuance changes.

What is claimed is:

1. A transcatheter, implantable, prosthetic heart valve, comprising:

a lattice frame; and

two or more integrated cusp and leaflet folded structures attached to the lattice frame, the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of biocompatible membrane that has been folded to include a mobile leaflet section and a cusp wall section, wherein non-transverse diagonally oriented folds that are angled relative to an axial flow direction are located between the mobile leaflet section and the cusp wall section, wherein the cusp wall section is located radially outside of the mobile leaflet section, and wherein the cusp wall section includes a seam that joins apposing sides of the cusp wall section.

2. The transcatheter, implantable, prosthetic heart valve of claim 1, wherein the two or more integrated cusp and leaflet folded structures are each attached along their respective seams to the lattice frame.

3. The transcatheter implantable, prosthetic heart valve of claim 2, wherein the seams are oriented in a direction substantially parallel to an axis of the lattice frame.

4. The transcatheter implantable, prosthetic heart valve of claim 1, wherein the flat sheet of biocompatible membrane forming at least one integrated cusp and leaflet folded structure of the two or more integrated cusp and leaflet folded structures comprises two or more pieces of biocompatible membrane material.

5. A transcatheter, implantable, prosthetic heart valve, comprising:

a lattice frame; and

two or more integrated cusp and leaflet folded structures attached to the lattice frame, the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of a biocompatible membrane that has been folded along non-transverse diagonal folds that are angled relative to an axial flow direction, wherein the folded biocompatible membrane includes a valve cusp according to a flat folding pattern.

6. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein two distal, downstream, vertices of each of the two or more integrated cusp and leaflet folded structures have been folded over at vertex folds in a radially outward direction and fixed to the lattice frame such that the vertex folds of circumferentially adjacent leaflets are adjacent and define a degree of leaflet apposition at points corresponding to leaflet commissures.

7. The transcatheter, implantable, prosthetic heart valve of claim 6, wherein the two distal, downstream, vertices are fixed to the lattice frame by attachment not along an alignment with the vertex folds.

8. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein a vertex forming a proximal, upstream, tip of the valve cusp has been folded over in a radially outward direction and attached to the lattice frame.

9. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the flat folding pattern is polygonal and includes extending portions that extend along a circumferential course to form an integral, inner, luminal, circumferentially complete sealing cuff.

10. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the flat folding pattern is polygonal and includes extending portions that extend along a circumferential course to form a circumferentially incomplete sealing cuff portion associated with each valve cusp.

11. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein a separate tubular cuff of biocompatible membrane has been attached to an outer, abluminal surface of the lattice frame to form a sealing cuff.

12. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as a tubular stent member.

13. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the biocompatible membrane comprises processed mammalian pericardium tissue.

14. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the biocompatible membrane does not comprise a treated tissue.

15. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the biocompatible membrane comprises a synthetic material.

16. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the two or more integrated cusp and leaflet folded structures are each further attached to a portion of the lattice frame along at least a portion of their distal downstream edges.

17. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein each of the two or more integrated cusp and leaflet folded structures are attached to the lattice frame at least at a seam circumferentially not coincident with a valve commissure, and wherein each seam is aligned substantially parallel to an axis of the lattice frame.

18. In subcombination, an integrated cusp and leaflet structure for attachment to a lattice frame to form a valve configured for implantation in a vascular system of a patient, the integrated cusp and leaflet structure comprising:

a flat sheet of a biocompatible membrane that has been folded to include a mobile leaflet section and a cusp wall section, wherein non-transverse diagonally oriented folds angled relative to an axial flow direction are located between the mobile leaflet section and the cusp wall section, wherein the cusp wall section is divided along a seam, and wherein the mobile leaflet section is continuous with the cusp wall section and apposes the cusp wall section when the mobile leaflet section is in a position corresponding to an open operating configuration.

19. The subcombination of claim 18, wherein the mobile leaflet section and the cusp wall section of the integrated cusp and leaflet structure are a continuous portion of a single piece of biocompatible membrane.

20. The subcombination of claim 18, wherein the biocompatible membrane comprises processed mammalian pericardium tissue.

21. The subcombination of claim 18, wherein the biocompatible membrane does not comprise a treated tissue.

22. The subcombination of claim 18, wherein the biocompatible membrane comprises a synthetic material.

23. The subcombination of claim 18, wherein the integrated cusp and leaflet structure further comprises at least one commissure tab.

24. The subcombination of claim 23, wherein the at least one commissure tab is configured for engaging a slot within a member of the lattice frame.

25. The transcatheter, implantable, prosthetic heart valve of claim 1, wherein the apposing sides of the cusp wall section include a left cusp wall portion and a right cusp wall portion, wherein a left cuff wall portion is continuous with the left cusp wall portion, and wherein a right cuff wall portion is continuous with the right cusp wall portion.

26. The transcatheter, implantable, prosthetic heart valve of claim 25, wherein the left cuff wall portion and the right cuff wall portion of each of the two or more integrated cusp and leaflet folded structures are joined at the seam of each of the two or more integrated cusp and leaflet folded structures.

27. The transcatheter, implantable, prosthetic heart valve of claim 25, wherein the left cuff wall portion and the right cuff wall portion reside radially exterior to the cusp wall section and the mobile leaflet section.

28. The transcatheter, implantable, prosthetic heart valve of claim 25, wherein the left cuff wall portion and the right cuff wall portion reside radially interior of the lattice frame.

29. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein each valve cusp of the two or more integrated cusp and leaflet folded structures comprise apposing sides that are joined along a seam.

30. The transcatheter, implantable, prosthetic heart valve of claim 29, wherein the two or more integrated cusp and leaflet folded structures are each attached along their respective seams to the lattice frame in a direction substantially parallel to an axis of the lattice frame.

31. The subcombination of claim 18, wherein the mobile leaflet section substantially matches a size of the cusp wall section.

32. The subcombination of claim 18, wherein the mobile leaflet section includes a left mobile leaflet portion and a right mobile leaflet portion, wherein the cusp wall section includes a left cusp wall portion and a right cusp wall portion, and wherein the left mobile leaflet portion apposes the left cusp wall portion and the right mobile leaflet portion apposes the right cusp wall portion.

33. The subcombination of claim 32, wherein each of the left mobile leaflet portion, right mobile leaflet portion, left cusp wall portion and right cusp wall portion are triangular in shape.

34. A transcatheter, implantable, prosthetic heart valve, comprising:

a lattice frame; and

two or more integrated cusp and leaflet folded structures attached to the lattice frame, the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of a biocompatible membrane that has been folded to include a valve cusp according to a flat folding pattern, wherein non-transverse diagonally oriented folds angled relative to an axial flow direction are located between a mobile leaflet section and a cusp wall section of each of the integrated cusp and leaflet folded structures, and wherein the flat folding pattern is polygonal and includes extending portions that extend along a circumferential course from the valve cusp and form at least a portion of an integral, inner, luminal, sealing cuff.

35. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the integral, inner, luminal, sealing cuff is circumferentially complete.

36. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the integral, inner, luminal, sealing cuff is circumferentially incomplete.

37. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein each valve cusp is divided along a seam that joins apposing sides of the valve cusp.

38. The transcatheter, implantable, prosthetic heart valve of claim 37, wherein the seam of each of the two or more integrated cusp and leaflet folded structures are each oriented substantially parallel to an axis of the lattice frame.

39. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein a vertex forming a proximal, upstream, tip of the valve cusp has been folded over in a radially outward direction and attached to the lattice frame.

40. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as a tubular stent member.

41. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the biocompatible membrane comprises processed mammalian pericardium tissue.

42. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the biocompatible membrane does not comprise a treated tissue.

43. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the biocompatible membrane comprises a synthetic material.

44. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the two or more integrated cusp and leaflet folded structures are attached to a portion of the lattice frame along a distal outflow portion of the lattice frame.

45. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein each of the two or more integrated cusp and leaflet folded structures are attached to the lattice frame at least at a seam circumferentially not coincident with a valve commissure, and wherein each seam is aligned substantially parallel to an axis of the lattice frame.

46. A transcatheter, implantable, prosthetic heart valve, comprising:

a lattice frame; and

two or more integrated cusp and leaflet folded structures attached to the lattice frame, the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of biocompatible membrane that has been folded to include a mobile leaflet section, a cusp wall section and a cuff wall section, wherein non-transverse diagonally oriented folds angled relative to an axial flow direction are located between the mobile leaflet section and the cusp wall section, wherein the mobile leaflet section apposes and substantially directly overlaps the cusp wall section, wherein the cuff wall section resides radially exterior to the cusp wall section and the mobile leaflet section, and wherein the cuff wall section resides adjacent a portion of a surface of the lattice frame.

47. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the portion of the surface of the lattice frame is an interior surface of the lattice frame.

48. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the two or more integrated cusp and leaflet folded structures each include a seam along apposing sides of the cusp wall section.

49. The transcatheter, implantable, prosthetic heart valve of claim 48, wherein the seams of the two or more integrated cusp and leaflet folded structures are each oriented substantially parallel to an axis of the lattice frame.

50. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein a vertex forming a proximal, upstream, tip of the mobile leaflet section is folded over in a radially outward direction and attached to the lattice frame.

51. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as a tubular stent member.

52. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the biocompatible membrane comprises processed mammalian pericardium tissue.

53. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the biocompatible membrane does not comprise a treated tissue.

54. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the biocompatible membrane comprises a synthetic material.

55. A vascular system implant, comprising:

a lattice frame; and

a plurality of substantially conical shaped cusps attached to the lattice frame, wherein each of the plurality of substantially conical shaped cusps includes a biocompatible membrane, and wherein each of the plurality of substantially conical shaped cusps include non-transverse diagonally oriented folds that are angled relative to an axial flow direction.

56. The vascular system implant of claim 55, wherein the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as a tubular stent member.

57. The vascular system implant of claim 55, wherein the biocompatible membrane comprises processed mammalian pericardium tissue.

58. The vascular system implant of claim 55, wherein the biocompatible membrane does not comprise a treated tissue.

59. The vascular system implant of claim 55, wherein the biocompatible membrane comprises a synthetic material.

60. A vascular system implant, comprising:

a lattice frame; and

a plurality of non-rectangular polygonal mobile leaflets attached to the lattice frame, wherein each of the plurality of non-rectangular polygonal mobile leaflets includes a biocompatible membrane, and wherein each of the plurality of non-rectangular polygonal mobile leaflets are bordered by non-transverse diagonally oriented folds that are angled relative to an axial flow direction.

61. The vascular system implant of claim 60, wherein each of the plurality of non-rectangular polygonal mobile leaflets is attached in a continuous manner to a corresponding cusp wall located radially exterior to each of the plurality of non-rectangular polygonal mobile leaflets.

62. The vascular system implant of claim 61, further comprising a cuff wall attached to the lattice frame, wherein the cuff wall is located radially exterior to each of the plurality of non-rectangular polygonal mobile leaflets and to the corresponding cusp wall.

63. The vascular system implant of claim 60, wherein the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as a tubular stent member.

64. The vascular system implant of claim 60, wherein the biocompatible membrane comprises processed mammalian pericardium tissue.

65. The vascular system implant of claim 60, wherein the biocompatible membrane does not comprise a treated tissue.

66. The vascular system implant of claim 60, wherein the biocompatible membrane comprises a synthetic material.

67. A vascular system implant, comprising:

a lattice frame; and

at least two folded biocompatible membrane sheets attached to the lattice frame, wherein each of the at least two folded biocompatible membrane sheets has been formed to include a non-rectangular polygonal mobile leaflet, wherein each of the non-rectangular polygonal mobile leaflets include non-transverse diagonally oriented folds that are angled relative to an axial flow direction.

68. The vascular system implant of claim 67, wherein each of the at least two folded biocompatible membrane sheets comprises two or more pieces of biocompatible membrane material.

69. The vascular system implant of claim 67, wherein the lattice frame is collapsible and expandable and comprises a metal alloy substantially configured as a tubular stent member.

70. The vascular system implant of claim 67, wherein the at least two folded biocompatible membrane sheets comprise processed mammalian pericardium tissue.

71. The vascular system implant of claim 67, wherein the at least two folded biocompatible membrane sheets do not comprise a treated tissue.

72. The vascular system implant of claim 67, wherein the at least two folded biocompatible membrane sheets comprise a synthetic material.

73. The transcatheter, implantable, prosthetic heart valve of claim 1, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

74. The transcatheter, implantable, prosthetic heart valve of claim 5, wherein the non-transverse diagonal folds are angled at between about 10 to 80 degrees from the axial flow direction.

75. The subcombination of claim 18, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

76. The transcatheter, implantable, prosthetic heart valve of claim 34, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

77. The transcatheter, implantable, prosthetic heart valve of claim 46, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

78. The vascular system implant of claim 55, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

79. The vascular system implant of claim 60, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

80. The vascular system implant of claim 67, wherein the non-transverse diagonally oriented folds are angled at between about 10 to 80 degrees from the axial flow direction.

81. The transcatheter, implantable, prosthetic heart valve of claim 1, wherein a vertex forming a proximal, upstream, tip of the mobile leaflet section has been folded over in a radially outward direction and attached to the lattice frame.

82. The subcombination of claim 18, wherein a vertex forming a proximal, upstream, tip of the mobile leaflet section has been folded over in a radially outward direction and attached to the lattice frame.

83. The vascular system implant of claim 55, wherein each of the plurality of conical shaped cusps includes a vertex forming a proximal, upstream, tip that has been folded over in a radially outward direction and attached to the lattice frame.

84. The vascular system implant of claim 62, wherein each of the plurality of non-rectangular polygonal mobile leaflets includes a vertex forming a proximal, upstream, tip that has been folded over in a radially outward direction and attached to the lattice frame.

85. The vascular system implant of claim 67, wherein each of the non-rectangular polygonal mobile leaflets includes a vertex forming a proximal, upstream, tip that has been folded over in a radially outward direction and attached to the lattice frame.

Patent Citations (546)

Patent	Date	Inventor	Cited By
US3014024(A)	1961-12-01	Lieberman et al.	Applicant
US3029819(A)	1962-04-01	Edward	Applicant
US3105492(A)	1963-10-01	Jeckel	Applicant
US3320972(A)	1967-05-01	High et al.	Applicant
US3409914(A)	1968-11-01	Jones	Applicant
US3548417(A)	1970-12-01	Kischer et al.	Applicant
US3562820(A)	1971-02-01	Braun	Applicant
US3588920(A)	1971-06-01	Wesolowski	Applicant
US3671979(A)	1972-06-01	Moulopoulos	Applicant
US3709175(A)	1973-01-01	Edwards et al.	Applicant
US3878565(A)	1975-04-01	Sauvage	Applicant
US3945052(A)	1976-03-01	Liebig	Applicant
US3966401(A)	1976-06-01	Hancock et al.	Applicant
US3983581(A)	1976-10-01	Angell et al.	Applicant
US3986828(A)	1976-10-01	Hoffman, Jr. et al.	Applicant
US4011947(A)	1977-03-01	Sawyer	Applicant
US4035849(A)	1977-07-01	Angell et al.	Applicant
US4055861(A)	1977-11-01	Carpentier et al.	Applicant
US4056854(A)	1977-11-01	Boretos et al.	Applicant
US4060081(A)	1977-11-01	Yannas et al.	Applicant
US4082507(A)	1978-04-01	Sawyer	Applicant
US4084268(A)	1978-04-01	Ionescu et al.	Applicant
US4106129(A)	1978-08-01	Carpentier et al.	Applicant
US4164045(A)	1979-08-01	Bokros et al.	Applicant
US4172295(A)	1979-10-01	Batten	Applicant
US4218782(A)	1980-08-01	Rygg	Applicant
US4222126(A)	1980-09-01	Boretos et al.	Applicant
US4233493(A)	1980-11-01	Nath	Applicant
US4265694(A)	1981-05-01	Boretos et al.	Applicant
US4275469(A)	1981-06-01	Gabbay	Applicant
US4291420(A)	1981-09-01	Reul	Applicant
US4340977(A)	1982-07-01	Brownlee et al.	Applicant
US4350492(A)	1982-09-01	Wright et al.	Applicant
US4364127(A)	1982-12-01	Pierce et al.	Applicant
US4388735(A)	1983-06-01	Ionescu et al.	Applicant
US4423525(A)	1984-01-01	Vallana et al.	Applicant
US4441216(A)	1984-04-01	Ionescu et al.	Applicant
US4456589(A)	1984-06-01	Holman et al.	Applicant
US4473423(A)	1984-09-01	Kolff	Applicant
US4477930(A)	1984-10-01	Totten et al.	Applicant
US4490859(A)	1985-01-01	Black et al.	Applicant
US4491986(A)	1985-01-01	Gabbay	Applicant
US4517687(A)	1985-05-01	Liebig et al.	Applicant
US4545082(A)	1985-10-01	Hood	Applicant
US4553974(A)	1985-11-01	Dewanjee	Applicant
US4597762(A)	1986-07-01	Walter et al.	Applicant
US4600533(A)	1986-07-01	Chu	Applicant
US4631052(A)	1986-12-01	Kensey	Applicant
US4657133(A)	1987-04-01	Komatsu et al.	Applicant
US4666442(A)	1987-05-01	Arru et al.	Applicant
US4692164(A)	1987-09-01	Dzemechkevich et al.	Applicant
US4728328(A)	1988-03-01	Hughes et al.	Applicant
US4743231(A)	1988-05-01	Kay et al.	Applicant
US4759758(A)	1988-07-01	Gabbay	Applicant
US4759759(A)	1988-07-01	Walker et al.	Applicant
US4798611(A)	1989-01-01	Freeman, Jr.	Applicant
US4801299(A)	1989-01-01	Brendel et al.	Applicant
US4870966(A)	1989-10-01	Dellon et al.	Applicant
US4883458(A)	1989-11-01	Shiber	Applicant
US4892539(A)	1990-01-01	Koch	Applicant
US4966604(A)	1990-10-01	Reiss	Applicant
US4976733(A)	1990-12-01	Girardot	Applicant
US4979939(A)	1990-12-01	Shiber	Applicant
US5006104(A)	1991-04-01	Smith et al.	Applicant
US5007896(A)	1991-04-01	Shiber	Applicant
US5011488(A)	1991-04-01	Ginsburg	Applicant
US5026366(A)	1991-06-01	Leckrone	Applicant
US5032128(A)	1991-07-01	Alonso	Applicant
US5047041(A)	1991-09-01	Samuels	Applicant
US5047050(A)	1991-09-01	Arpesani	Applicant
US5052771(A)	1991-10-01	Williams et al.	Applicant
US5061277(A)	1991-10-01	Carpentier et al.	Applicant
US5080660(A)	1992-01-01	Buelna	Applicant
US5080670(A)	1992-01-01	Imamura	Applicant
US5139515(A)	1992-08-01	Robicsek	Applicant
US5163955(A)	1992-11-01	Love et al.	Applicant
US5171273(A)	1992-12-01	Silver et al.	Applicant
US5226889(A)	1993-07-01	Sheiban	Applicant
US5261878(A)	1993-11-01	Galindo	Applicant
US5282847(A)	1994-02-01	Trescony et al.	Applicant
US5326370(A)	1994-07-01	Love et al.	Applicant
US5326371(A)	1994-07-01	Love et al.	Applicant
US5332402(A)	1994-07-01	Teitelbaum	Applicant
US5336616(A)	1994-08-01	Livesey et al.	Applicant
US5344442(A)	1994-09-01	Deac	Applicant
US5360443(A)	1994-11-01	Barone et al.	Applicant
US5374539(A)	1994-12-01	Nimni et al.	Applicant
US5376110(A)	1994-12-01	Tu et al.	Applicant
US5383927(A)	1995-01-01	De Goicoechea et al.	Applicant
US5411552(A)	1995-05-01	Andersen et al.	Applicant
US5413601(A)	1995-05-01	Keshelava	Applicant
US5449384(A)	1995-09-01	Johnson	Applicant
US5476506(A)	1995-12-01	Lunn	Applicant
US5480424(A)	1996-01-01	Cox	Applicant
US5484444(A)	1996-01-01	Braunschweiler et al.	Applicant
US5489297(A)	1996-02-01	Duran	Applicant
US5500015(A)	1996-03-01	Deac	Applicant
US5509930(A)	1996-04-01	Love	Applicant
US5522879(A)	1996-06-01	Scopelianos	Applicant
US5522881(A)	1996-06-01	Lentz	Applicant
US5545215(A)	1996-08-01	Duran	Applicant
US5549664(A)	1996-08-01	Hirata et al.	Applicant
US5549666(A)	1996-08-01	Hara et al.	Applicant
US5554184(A)	1996-09-01	Machiraju	Applicant
US5558875(A)	1996-09-01	Wang	Applicant
US5571170(A)	1996-11-01	Palmaz et al.	Applicant
US5571173(A)	1996-11-01	Parodi	Applicant
US5571174(A)	1996-11-01	Love et al.	Applicant
US5578071(A)	1996-11-01	Parodi	Applicant
US5578072(A)	1996-11-01	Barone et al.	Applicant
US5582168(A)	1996-12-01	Samuels et al.	Applicant
US5591229(A)	1997-01-01	Parodi	Applicant
US5634928(A)	1997-06-01	Fischell	Applicant
US5653749(A)	1997-08-01	Love et al.	Applicant
US5713953(A)	1998-02-01	Vallana et al.	Applicant
US5728152(A)	1998-03-01	Mirsch, II et al.	Applicant
US5733299(A)	1998-03-01	Sheiban et al.	Applicant
US5741333(A)	1998-04-01	Frid	Applicant
US5746775(A)	1998-05-01	Levy et al.	Applicant
US5769780(A)	1998-06-01	Hata et al.	Applicant
US5782914(A)	1998-07-01	Schankereli	Applicant
US5787887(A)	1998-08-01	Klingenbeck-Regn	Applicant
US5840081(A)	1998-11-01	Andersen et al.	Applicant
US5855597(A)	1999-01-01	Jayaraman	Applicant
US5855601(A)	1999-01-01	Bessler et al.	Applicant
US5861028(A)	1999-01-01	Angell	Applicant
US5862806(A)	1999-01-01	Cheung	Applicant
US5895420(A)	1999-04-01	Mirsch, II et al.	Applicant
US5957949(A)	1999-09-01	Leonhardt et al.	Applicant
US5961539(A)	1999-10-01	Northrup et al.	Applicant
US5961549(A)	1999-10-01	Nguyen et al.	Applicant
US5972030(A)	1999-10-01	Garrison et al.	Applicant
US5976179(A)	1999-11-01	Inoue	Applicant
US6004328(A)	1999-12-01	Solar	Applicant
US6004330(A)	1999-12-01	Middleman et al.	Applicant
US6010531(A)	2000-01-01	Donlon et al.	Applicant
US6029671(A)	2000-02-01	Stevens et al.	Applicant
US6045576(A)	2000-04-01	Starr et al.	Applicant
US6053938(A)	2000-04-01	Goldmann et al.	Applicant
US6091984(A)	2000-07-01	Perelman et al.	Applicant
US6102944(A)	2000-08-01	Huynh et al.	Applicant
US6117169(A)	2000-09-01	Moe	Applicant
US6124523(A)	2000-09-01	Banas et al.	Applicant
US6125852(A)	2000-10-01	Stevens et al.	Applicant
US6126686(A)	2000-10-01	Badylak et al.	Applicant
US6129756(A)	2000-10-01	Kugler	Applicant
US6162245(A)	2000-12-01	Jayaraman	Applicant
US6168614(B1)	2001-01-01	Andersen et al.	Applicant
US6168619(B1)	2001-01-01	Dinh et al.	Applicant
US6171335(B1)	2001-01-01	Wheatley et al.	Applicant
US6174327(B1)	2001-01-01	Mertens et al.	Applicant
US6186999(B1)	2001-02-01	Chen	Applicant
US6197143(B1)	2001-03-01	Bodnar	Applicant
US6214055(B1)	2001-04-01	Simionescu et al.	Applicant
US6221091(B1)	2001-04-01	Khosravi	Applicant
US6231602(B1)	2001-05-01	Carpentier et al.	Applicant
US6245102(B1)	2001-06-01	Jayaraman	Applicant
US6254629(B1)	2001-07-01	Inoue	Applicant
US6254630(B1)	2001-07-01	Inoue	Applicant
US6254636(B1)	2001-07-01	Peredo	Applicant
US6264691(B1)	2001-07-01	Gabbay	Applicant
US6269819(B1)	2001-08-01	Oz et al.	Applicant
US6270526(B1)	2001-08-01	Cox	Applicant
US6277397(B1)	2001-08-01	Shimizu	Applicant
US6277555(B1)	2001-08-01	Duran et al.	Applicant
US6287335(B1)	2001-09-01	Drasler	Applicant
US6293970(B1)	2001-09-01	Wolfinbarger et al.	Applicant
US6312462(B1)	2001-11-01	McDermott et al.	Applicant
US6312474(B1)	2001-11-01	Francis et al.	Applicant
US6334873(B1)	2002-01-01	Lane et al.	Applicant
US6342069(B1)	2002-01-01	Deac et al.	Applicant
US6350282(B1)	2002-02-01	Eberhardt	Applicant
US6352554(B2)	2002-03-01	De Paulis	Applicant
US6352708(B1)	2002-03-01	Duran et al.	Applicant
US6358275(B1)	2002-03-01	McIlroy et al.	Applicant
US6358284(B1)	2002-03-01	Fearnot et al.	Applicant
US6371980(B1)	2002-04-01	Rudakov et al.	Applicant
US6376244(B1)	2002-04-01	Atala et al.	Applicant
US6378221(B1)	2002-04-01	Ekholm, Jr. et al.	Applicant
US6383171(B1)	2002-05-01	Gifford et al.	Applicant
US6391333(B1)	2002-05-01	Li et al.	Applicant
US6409755(B1)	2002-06-01	Vrba	Applicant
US6418339(B1)	2002-07-01	Essenpreis et al.	Applicant
US6425916(B1)	2002-07-01	Garrison et al.	Applicant
US6432712(B1)	2002-08-01	Wolfinbarger, Jr. et al.	Applicant
US6440167(B2)	2002-08-01	Shimizu	Applicant
US6458153(B1)	2002-10-01	Bailey et al.	Applicant
US6461382(B1)	2002-10-01	Cao	Applicant
US6468313(B1)	2002-10-01	Claeson et al.	Applicant
US6471723(B1)	2002-10-01	Ashworth et al.	Applicant
US6482227(B1)	2002-11-01	Solovay	Applicant
US6482228(B1)	2002-11-01	Norred	Applicant
US6482240(B1)	2002-11-01	Eckmayer et al.	Applicant
US6491719(B1)	2002-12-01	Fogarty et al.	Applicant
US6494909(B2)	2002-12-01	Greenhalgh	Applicant
US6503272(B2)	2003-01-01	Duerig et al.	Applicant
US6534004(B2)	2003-03-01	Chen et al.	Applicant
US6540782(B1)	2003-04-01	Snyders	Applicant
US6553681(B2)	2003-04-01	Ekholm, Jr. et al.	Applicant
US6558418(B2)	2003-05-01	Carpentier et al.	Applicant
US6565960(B2)	2003-05-01	Koob et al.	Applicant
US6569200(B2)	2003-05-01	Wolfinbarger, Jr. et al.	Applicant
US6582458(B1)	2003-06-01	White et al.	Applicant
US6582462(B1)	2003-06-01	Andersen et al.	Applicant
US6582464(B2)	2003-06-01	Gabbay	Applicant
US6599524(B2)	2003-07-01	Li et al.	Applicant
US6610088(B1)	2003-08-01	Gabbay	Applicant
US6624890(B2)	2003-09-01	Backman et al.	Applicant
US6626938(B1)	2003-09-01	Butaric et al.	Applicant
US6652577(B2)	2003-11-01	Gianotti	Applicant
US6652578(B2)	2003-11-01	Bailey et al.	Applicant
US6666886(B1)	2003-12-01	Tranquillo et al.	Applicant
US6676698(B2)	2004-01-01	McGuckin, Jr.	Applicant
US6682559(B2)	2004-01-01	Myers et al.	Applicant
US6685739(B2)	2004-02-01	Dimatteo et al.	Applicant
US6696074(B2)	2004-02-01	Dai et al.	Applicant
US6702826(B2)	2004-03-01	Liddicoat et al.	Applicant
US6719788(B2)	2004-04-01	Cox	Applicant
US6719789(B2)	2004-04-01	Cox	Applicant
US6733525(B2)	2004-05-01	Yang et al.	Applicant
US6736823(B2)	2004-05-01	Darois et al.	Applicant
US6764510(B2)	2004-07-01	Vidlund et al.	Applicant
US6773456(B1)	2004-08-01	Gordon et al.	Applicant
US6773457(B2)	2004-08-01	Ivancev	Applicant
US6790229(B1)	2004-09-01	Berreklouw	Applicant
US6792979(B2)	2004-09-01	Konya et al.	Applicant
US6802319(B2)	2004-10-01	Stevens et al.	Applicant
US6802806(B2)	2004-10-01	McCarthy et al.	Applicant
US6821297(B2)	2004-11-01	Snyders	Applicant
US6821530(B2)	2004-11-01	Koob et al.	Applicant
US6830584(B1)	2004-12-01	Seguin	Applicant
US6893460(B2)	2005-05-01	Spenser et al.	Applicant
US6908481(B2)	2005-06-01	Cribier	Applicant
US6913608(B2)	2005-07-01	Liddicoat et al.	Applicant
US6916338(B2)	2005-07-01	Speziali	Applicant
US6942694(B2)	2005-09-01	Liddicoat et al.	Applicant
US6951571(B1)	2005-10-01	Srivastava	Applicant
US6961123(B1)	2005-11-01	Wang et al.	Applicant
US6977231(B1)	2005-12-01	Matsuda	Applicant
US6986735(B2)	2006-01-01	Abraham et al.	Applicant
US7004925(B2)	2006-02-01	Navia et al.	Applicant
US7008763(B2)	2006-03-01	Cheung	Applicant
US7011688(B2)	2006-03-01	Gryska et al.	Applicant
US7018404(B2)	2006-03-01	Holmberg et al.	Applicant
US7018406(B2)	2006-03-01	Seguin et al.	Applicant
US7022348(B2)	2006-04-01	Ketharanathan	Applicant
US7025780(B2)	2006-04-01	Gabbay	Applicant
US7037333(B2)	2006-05-01	Myers et al.	Applicant
US7039446(B2)	2006-05-01	Ruchti et al.	Applicant
US7041132(B2)	2006-05-01	Quijano et al.	Applicant
US7053051(B2)	2006-05-01	Hendriks et al.	Applicant
US7060092(B2)	2006-06-01	Kuribayashi et al.	Applicant
US7070616(B2)	2006-07-01	Majercak et al.	Applicant
US7077862(B2)	2006-07-01	Vidlund et al.	Applicant
US7084082(B1)	2006-08-01	Shimizu	Applicant
US7138226(B2)	2006-11-01	Vincek et al.	Applicant
US7153324(B2)	2006-12-01	Case et al.	Applicant
US7160322(B2)	2007-01-01	Gabbay	Applicant
US7164145(B2)	2007-01-01	Shakespeare	Applicant
US7166570(B2)	2007-01-01	Hunter et al.	Applicant
US7189259(B2)	2007-03-01	Simionescu et al.	Applicant
US7213601(B2)	2007-05-01	Stevens et al.	Applicant
US7214242(B2)	2007-05-01	Abraham et al.	Applicant
US7214344(B2)	2007-05-01	Carpentier et al.	Applicant
US7232461(B2)	2007-06-01	Ramer	Applicant
US7261732(B2)	2007-08-01	Justino	Applicant
US7289211(B1)	2007-10-01	Walsh, Jr. et al.	Applicant
US7309461(B2)	2007-12-01	Kujawski et al.	Applicant
US7311730(B2)	2007-12-01	Gabbay	Applicant
US7318998(B2)	2008-01-01	Goldstein et al.	Applicant
US7329279(B2)	2008-02-01	Haug et al.	Applicant
US7331993(B2)	2008-02-01	White	Applicant
US7354702(B2)	2008-04-01	Dai et al.	Applicant
USRE40404(E)	2008-06-01	Schmitt et al.	Applicant
US7381218(B2)	2008-06-01	Schreck	Applicant
US7381219(B2)	2008-06-01	Salahieh et al.	Applicant
US7399315(B2)	2008-07-01	Iobbi	Applicant
US7427291(B2)	2008-09-01	Liddicoat et al.	Applicant
US7431725(B2)	2008-10-01	Stack et al.	Applicant
US7468073(B2)	2008-12-01	Johnson et al.	Applicant
US7473237(B2)	2009-01-01	Navia et al.	Applicant
US7481838(B2)	2009-01-01	Carpentier et al.	Applicant
US7503929(B2)	2009-03-01	Johnson et al.	Applicant
US7510571(B2)	2009-03-01	Spiridigliozzi et al.	Applicant
US7510575(B2)	2009-03-01	Spenser et al.	Applicant
US7524330(B2)	2009-04-01	Berreklouw	Applicant
US7566343(B2)	2009-07-01	Jenson et al.	Applicant
US7585321(B2)	2009-09-01	Cribier	Applicant
US7604661(B2)	2009-10-01	Pavcnik et al.	Applicant
US7618446(B2)	2009-11-01	Andersen et al.	Applicant
US7622276(B2)	2009-11-01	Cunanan et al.	Applicant
US7628805(B2)	2009-12-01	Spenser et al.	Applicant
US7648676(B2)	2010-01-01	Mills et al.	Applicant
US7670368(B2)	2010-03-01	Hill et al.	Applicant
US7708775(B2)	2010-05-01	Rowe et al.	Applicant
US7758632(B2)	2010-07-01	Hojeibane et al.	Applicant
US7780722(B2)	2010-08-01	Thielen et al.	Applicant
US7789909(B2)	2010-09-01	Andersen et al.	Applicant
US7846203(B2)	2010-12-01	Cribier	Applicant
US7846204(B2)	2010-12-01	Letac et al.	Applicant
US7871431(B2)	2011-01-01	Gurm et al.	Applicant
US7892281(B2)	2011-02-01	Seguin et al.	Applicant
US7914576(B2)	2011-03-01	Navia et al.	Applicant
USRE42395(E)	2011-05-01	Wright et al.	Applicant
US7967833(B2)	2011-06-01	Sterman et al.	Applicant
US7981151(B2)	2011-07-01	Rowe	Applicant
US8002825(B2)	2011-08-01	Letac et al.	Applicant
US8007992(B2)	2011-08-01	Tian et al.	Applicant
US8057540(B2)	2011-11-01	Letac et al.	Applicant
US8080054(B2)	2011-12-01	Rowe	Applicant
US8105375(B2)	2012-01-01	Navia et al.	Applicant
US8308797(B2)	2012-11-01	Paniagua et al.	Applicant
US8512401(B2)	2013-08-01	Murray et al.	Applicant
US8512403(B2)	2013-08-01	Navia et al.	Applicant
US8790398(B2)	2014-07-01	Paniagua et al.	Applicant
US2001/0010017(A1)	2001-07-01	Letac et al.	Applicant
US2001/0023372(A1)	2001-09-01	Chen et al.	Applicant
US2001/0049558(A1)	2001-12-01	Liddicoat et al.	Applicant
US2002/0005073(A1)	2002-01-01	Tompkins et al.	Applicant
US2002/0028243(A1)	2002-03-01	Masters	Applicant
US2002/0029783(A1)	2002-03-01	Stevens et al.	Applicant
US2002/0032481(A1)	2002-03-01	Gabbay	Applicant
US2002/0032482(A1)	2002-03-01	Cox	Applicant
US2002/0037940(A1)	2002-03-01	Koob et al.	Applicant
US2002/0042621(A1)	2002-04-01	Liddicoat et al.	Applicant
US2002/0052651(A1)	2002-05-01	Myers et al.	Applicant
US2002/0055772(A1)	2002-05-01	McGuckin, Jr. et al.	Applicant
US2002/0091441(A1)	2002-07-01	Guzik	Applicant
US2002/0095167(A1)	2002-07-01	Liddicoat et al.	Applicant
US2002/0095994(A1)	2002-07-01	Vesely et al.	Applicant
US2002/0099439(A1)	2002-07-01	Schwartz et al.	Applicant
US2002/0119437(A1)	2002-08-01	Grooms et al.	Applicant
US2002/0123789(A1)	2002-09-01	Francis et al.	Applicant
US2002/0128708(A1)	2002-09-01	Northrup et al.	Applicant
US2002/0146393(A1)	2002-10-01	Bell et al.	Applicant
US2002/0151970(A1)	2002-10-01	Garrison et al.	Applicant
US2002/0198594(A1)	2002-12-01	Schreck	Applicant
US2003/0027332(A1)	2003-02-01	Lafrance et al.	Applicant
US2003/0078659(A1)	2003-04-01	Yang	Applicant
US2003/0102000(A1)	2003-06-01	Stevens et al.	Applicant
US2003/0118560(A1)	2003-06-01	Kelly et al.	Applicant
US2003/0130727(A1)	2003-07-01	Drasler et al.	Applicant
US2003/0130729(A1)	2003-07-01	Paniagua et al.	Applicant
US2003/0130731(A1)	2003-07-01	Vidlund et al.	Applicant
US2003/0138945(A1)	2003-07-01	McAllister	Applicant
US2003/0149477(A1)	2003-08-01	Gabbay	Applicant
US2003/0153974(A1)	2003-08-01	Spenser et al.	Applicant
US2003/0187362(A1)	2003-10-01	Murphy et al.	Applicant
US2003/0195620(A1)	2003-10-01	Huynh et al.	Applicant
US2003/0204023(A1)	2003-10-01	Koob et al.	Applicant
US2003/0209835(A1)	2003-11-01	Chun et al.	Applicant
US2003/0212460(A1)	2003-11-01	Darois et al.	Applicant
US2003/0212462(A1)	2003-11-01	Gryska et al.	Applicant
US2003/0217415(A1)	2003-11-01	Crouch et al.	Applicant
US2004/0024452(A1)	2004-02-01	Kruse et al.	Applicant
US2004/0039442(A1)	2004-02-01	St. Goar	Applicant
US2004/0049262(A1)	2004-03-01	Obermiller et al.	Applicant
US2004/0055608(A1)	2004-03-01	Stevens et al.	Applicant
US2004/0059418(A1)	2004-03-01	McKay et al.	Applicant
US2004/0098092(A1)	2004-05-01	Butaric et al.	Applicant
US2004/0158321(A1)	2004-08-01	Reuter et al.	Applicant
US2004/0193261(A1)	2004-09-01	Berreklouw	Applicant
US2004/0230285(A1)	2004-11-01	Gifford, III et al.	Applicant
US2004/0243153(A1)	2004-12-01	Liddicoat et al.	Applicant
US2004/0243229(A1)	2004-12-01	Vidlund et al.	Applicant
US2005/0004668(A1)	2005-01-01	Aklog et al.	Applicant
US2005/0027369(A1)	2005-02-01	Eldridge et al.	Applicant
US2005/0043819(A1)	2005-02-01	Schmidt et al.	Applicant
US2005/0096673(A1)	2005-05-01	Stack et al.	Applicant
US2005/0113910(A1)	2005-05-01	Paniagua et al.	Applicant
US2005/0137681(A1)	2005-06-01	Shoemaker et al.	Applicant
US2005/0137682(A1)	2005-06-01	Justino	Applicant
US2005/0142163(A1)	2005-06-01	Hunter et al.	Applicant
US2005/0147562(A1)	2005-07-01	Hunter et al.	Applicant
US2005/0147599(A1)	2005-07-01	Hunter et al.	Applicant
US2005/0147643(A1)	2005-07-01	Hunter et al.	Applicant
US2005/0148512(A1)	2005-07-01	Hunter et al.	Applicant
US2005/0158274(A1)	2005-07-01	Hunter et al.	Applicant
US2005/0159811(A1)	2005-07-01	Lane	Applicant
US2005/0169958(A1)	2005-08-01	Hunter et al.	Applicant
US2005/0169959(A1)	2005-08-01	Hunter et al.	Applicant
US2005/0175657(A1)	2005-08-01	Hunter et al.	Applicant
US2005/0187618(A1)	2005-08-01	Gabbay	Applicant
US2005/0191248(A1)	2005-09-01	Hunter et al.	Applicant
US2005/0228494(A1)	2005-10-01	Marquez	Applicant
US2005/0241981(A1)	2005-11-01	Gupta et al.	Applicant
US2005/0246035(A1)	2005-11-01	Wolfinbarger, Jr. et al.	Applicant
US2005/0247320(A1)	2005-11-01	Stack et al.	Applicant
US2005/0267529(A1)	2005-12-01	Crockett et al.	Applicant
US2006/0004439(A1)	2006-01-01	Spenser et al.	Applicant
US2006/0004443(A1)	2006-01-01	Liddicoat et al.	Applicant
US2006/0020336(A1)	2006-01-01	Liddicoat	Applicant
US2006/0025800(A1)	2006-02-01	Suresh	Applicant
US2006/0041306(A1)	2006-02-01	Vidlund et al.	Applicant
US2006/0074486(A1)	2006-04-01	Liddicoat et al.	Applicant
US2006/0089708(A1)	2006-04-01	Osse et al.	Applicant
US2006/0111733(A1)	2006-05-01	Shriver	Applicant
US2006/0129225(A1)	2006-06-01	Kopia et al.	Applicant
US2006/0134079(A1)	2006-06-01	Sih et al.	Applicant
US2006/0140916(A1)	2006-06-01	Siani-Rose et al.	Applicant
US2006/0155366(A1)	2006-07-01	Ls Duca et al.	Applicant
US2006/0173475(A1)	2006-08-01	Lafontaine et al.	Applicant
US2006/0178740(A1)	2006-08-01	Stacchino et al.	Applicant
US2006/0190074(A1)	2006-08-01	Hill et al.	Applicant
US2006/0193885(A1)	2006-08-01	Neethling et al.	Applicant
US2006/0195010(A1)	2006-08-01	Arnal et al.	Applicant
US2006/0195183(A1)	2006-08-01	Navia et al.	Applicant
US2006/0206203(A1)	2006-09-01	Yang et al.	Applicant
US2006/0212111(A1)	2006-09-01	Case et al.	Applicant
US2006/0229701(A1)	2006-10-01	Gurm et al.	Applicant
US2006/0229716(A1)	2006-10-01	Mitrev	Applicant
US2006/0240063(A9)	2006-10-01	Hunter et al.	Applicant
US2006/0240064(A9)	2006-10-01	Hunter et al.	Applicant
US2006/0259134(A1)	2006-11-01	Schwammenthal et al.	Applicant
US2006/0259135(A1)	2006-11-01	Navia et al.	Applicant
US2006/0259137(A1)	2006-11-01	Artof et al.	Applicant
US2006/0265056(A1)	2006-11-01	Nguyen et al.	Applicant
US2006/0287571(A1)	2006-12-01	Gozzi et al.	Applicant
US2006/0292125(A1)	2006-12-01	Kellar et al.	Applicant
US2007/0010857(A1)	2007-01-01	Sugimoto et al.	Applicant
US2007/0043431(A1)	2007-02-01	Melsheimer	Applicant
US2007/0050014(A1)	2007-03-01	Johnson	Applicant
US2007/0050022(A1)	2007-03-01	Vidlund et al.	Applicant
US2007/0056346(A1)	2007-03-01	Spenser et al.	Applicant
US2007/0060932(A1)	2007-03-01	Stack et al.	Applicant
US2007/0061008(A1)	2007-03-01	Salahieh et al.	Applicant
US2007/0100426(A1)	2007-05-01	Rudakov et al.	Applicant
US2007/0104395(A1)	2007-05-01	Kinigakis et al.	Applicant
US2007/0128174(A1)	2007-06-01	Kleinsek et al.	Applicant
US2007/0173861(A1)	2007-07-01	Strommer et al.	Applicant
US2007/0203575(A1)	2007-08-01	Forster et al.	Applicant
US2007/0213813(A1)	2007-09-01	Von Segesser et al.	Applicant
US2007/0233228(A1)	2007-10-01	Eberhardt et al.	Applicant
US2007/0250154(A1)	2007-10-01	Greenberg et al.	Applicant
US2007/0263226(A1)	2007-11-01	Kurtz et al.	Applicant
US2007/0276432(A1)	2007-11-01	Stack et al.	Applicant
US2007/0276461(A1)	2007-11-01	Andreas et al.	Applicant
US2008/0004686(A1)	2008-01-01	Hunt et al.	Applicant
US2008/0009667(A1)	2008-01-01	Longhini et al.	Applicant
US2008/0009940(A1)	2008-01-01	Cribier	Applicant
US2008/0029105(A1)	2008-02-01	Stevens et al.	Applicant
US2008/0039871(A1)	2008-02-01	Wallace et al.	Applicant
US2008/0039926(A1)	2008-02-01	Majercak et al.	Applicant
US2008/0058798(A1)	2008-03-01	Wallace et al.	Applicant
US2008/0082113(A1)	2008-04-01	Bishop et al.	Applicant
US2008/0102439(A1)	2008-05-01	Tian et al.	Applicant
US2008/0131522(A1)	2008-06-01	Liu et al.	Applicant
US2008/0133004(A1)	2008-06-01	White	Applicant
US2008/0147182(A1)	2008-06-01	Righini et al.	Applicant
US2008/0154356(A1)	2008-06-01	Obermiller et al.	Applicant
US2008/0177381(A1)	2008-07-01	Navia et al.	Applicant
US2008/0183280(A1)	2008-07-01	Agnew et al.	Applicant
US2008/0183283(A1)	2008-07-01	Downing	Applicant
US2008/0190989(A1)	2008-08-01	Crews et al.	Applicant
US2008/0195200(A1)	2008-08-01	Vidlund et al.	Applicant
US2008/0199843(A1)	2008-08-01	Haverich et al.	Applicant
US2008/0200977(A1)	2008-08-01	Paul et al.	Applicant
US2009/0005857(A1)	2009-01-01	Ischinger	Applicant
US2009/0030511(A1)	2009-01-01	Paniagua et al.	Applicant
US2009/0043383(A1)	2009-02-01	McGregor et al.	Applicant
US2009/0054969(A1)	2009-02-01	Salahieh	Applicant
US2009/0054976(A1)	2009-02-01	Tuval et al.	Applicant
US2009/0062907(A1)	2009-03-01	Quijano et al.	Applicant
US2009/0112309(A1)	2009-04-01	Jaramillo et al.	Applicant
US2009/0132032(A9)	2009-05-01	Cribier	Applicant
US2009/0157175(A1)	2009-06-01	Benichou	Applicant
US2009/0164005(A1)	2009-06-01	Dove et al.	Applicant
US2009/0187241(A1)	2009-07-01	Melsheimer	Applicant
US2009/0248149(A1)	2009-10-01	Gabbay	Applicant
US2009/0254175(A1)	2009-10-01	Quijano et al.	Applicant
US2009/0281609(A1)	2009-11-01	Benichou et al.	Applicant
US2010/0030259(A1)	2010-02-01	Pavcnik et al.	Applicant
US2010/0036479(A1)	2010-02-01	Hill et al.	Applicant
US2010/0036484(A1)	2010-02-01	Hariton et al.	Applicant
US2010/0043197(A1)	2010-02-01	Abbate et al.	Applicant
US2010/0048987(A1)	2010-02-01	Khairkhahan	Applicant
US2010/0049312(A1)	2010-02-01	Edoga et al.	Applicant
US2010/0131054(A1)	2010-05-01	Tuval et al.	Applicant
US2010/0161036(A1)	2010-06-01	Pintor et al.	Applicant
US2010/0185277(A1)	2010-07-01	Braido et al.	Applicant
US2010/0217382(A1)	2010-08-01	Chau et al.	Applicant
US2010/0234878(A1)	2010-09-01	Hruska	Applicant
US2010/0241069(A1)	2010-09-01	Hatten	Applicant
US2010/0249918(A1)	2010-09-01	Zhang	Applicant
US2010/0256749(A1)	2010-10-01	Tran et al.	Applicant
US2010/0256751(A1)	2010-10-01	Rowe et al.	Applicant
US2010/0312333(A1)	2010-12-01	Navia et al.	Applicant
US2011/0004295(A1)	2011-01-01	Wittens	Applicant
US2011/0004299(A1)	2011-01-01	Navia et al.	Applicant
US2011/0015728(A1)	2011-01-01	Jiminez et al.	Applicant
US2011/0040375(A1)	2011-02-01	Letac et al.	Applicant
US2011/0087322(A1)	2011-04-01	Letac et al.	Applicant
US2011/0137409(A1)	2011-06-01	Yang et al.	Applicant
US2011/0146361(A1)	2011-06-01	Davidson et al.	Applicant
US2011/0153009(A1)	2011-06-01	Navia et al.	Applicant
US2011/0166636(A1)	2011-07-01	Rowe	Applicant
US2011/0178597(A9)	2011-07-01	Navia et al.	Applicant
US2011/0218619(A1)	2011-09-01	Benichou et al.	Applicant
US2011/0224607(A1)	2011-09-01	Vogelbaum et al.	Applicant
US2011/0240511(A1)	2011-10-01	Bolton et al.	Applicant
US2011/0300625(A1)	2011-12-01	Paniagua et al.	Applicant
US2011/0301700(A1)	2011-12-01	Fish et al.	Applicant
US2012/0078343(A1)	2012-03-01	Fish et al.	Applicant
US2012/0078356(A1)	2012-03-01	Fish et al.	Applicant
US2012/0095551(A1)	2012-04-01	Navia et al.	Applicant
US2012/0158128(A1)	2012-06-01	Gautam et al.	Applicant
US2012/0310041(A1)	2012-12-01	Paniagua et al.	Applicant
US2013/0304201(A1)	2013-11-01	Navia et al.	Applicant
US2014/0039613(A1)	2014-02-01	Navia et al.	Applicant
EP1603493	2005-12-01		Applicant
EP2000115	2011-05-01		Applicant
EP1441672	2011-09-01		Applicant
EP2055266	2012-02-01		Applicant
EP1621162	2012-05-01		Applicant
EP2260796	2013-02-01		Applicant
JP9-501594	1997-02-01		Applicant
JP2001-500761	2001-01-01		Applicant
JP2005-103321	2005-04-01		Applicant
RU2355361(C)	2009-05-01		Applicant
WO91-17720	1991-11-01		Applicant
WO92-17118	1992-10-01		Applicant
WO98/29057	1998-07-01		Applicant
WO99/30646	1999-06-01		Applicant
WO/12164	2000-03-01		Applicant
WO1-02031	2001-01-01		Applicant
WO3/047468	2003-06-01		Applicant
WO3-092554	2003-11-01		Applicant
WO2004/026124	2004-04-01		Applicant
WO2004/082527	2004-09-01		Applicant
WO2006-095342	2006-09-01		Applicant
WO2007-138572	2007-12-01		Applicant
WO2008/082527	2008-07-01		Applicant
WO2008/063537	2008-08-01		Applicant
WO2008/106531	2008-09-01		Applicant
WO2009-052188	2009-04-01		Applicant
WO2009/149462	2009-12-01		Applicant
WO2009-156471	2009-12-01		Applicant
WO2010/024801	2010-03-01		Applicant
WO2010/027363	2010-03-01		Applicant
WO2010/117541	2010-10-01		Applicant
WO2010/141847	2010-12-01		Applicant
WO2011-109433	2011-03-01		Applicant
WO2011-109450	2011-09-01		Applicant
WO2012-006124	2012-01-01		Applicant
WO2012/040643	2012-03-01		Applicant
WO2012/082952	2012-06-01		Applicant

Non-Patent Literature (118)

Sacks, Michael S. et al., “Orthotropic Mechanical Properties of Chemically Treated Bovine Pericardium” Annals of Biomedical Engineering, 1998, vol. 26, pp. 892-902.Applicant
Office Action issued in Japanese Application No. 2013-544758, dated Nov. 4, 2015.Applicant
Pohl, M. et al., “In vitro testing of artificial heart valves; comparison between Newtonian and non-Newtonian fluids” Artif Argns, Jan. 1996; 20(1); pp. 37-46.Applicant
Purinya, B. et al., “Biomechanical and Structural Properties of the Explanted Bioprosthetic Valve Leaflets” J. of Biomechanis, vol. 27, Iss 1, Jan. 1994 pp. 1-11 Elsevier Science Ltd, 1993.Applicant
Sacks, M S et al., “Collagen fiber architecture of bovine pericardium” ASAIO J, Jul. 1, 1994, 40(3):M632-7.Applicant
Sacks, M S et al., “A small angle light scattering device for planar connective tissue miscrostructural analysis” Ann Biomed Eng, Jul. 1, 1997, 254(4); 678-89.Applicant
Sacks, Michael S, “Incorporation of experimentally-derived fiber orientation into a structural constitutive model for planar collagenous tissues” J. Biomech Eng, Apr. 1, 2003, 125(2); 280-7.Applicant
Sacks, Michael S. et al., “Quantification of the fiber architecture and biaxial mechanical behavior of porcine intestinal submucosa” J of Biomedical Research, vol. 46, Iss 1, Jul. 1999, pp. 1-10.Applicant
Samouillan, V. et al., “Comparison of chemical treatments on the chain dynamics and thermal stability of bovine pericardium collagen” J Biomed Mater Res A. Feb. 1, 2003;64(2):330-8.Applicant
Schoen, Frederick J., “Tissue heart valves: Current challenges and future research perspectives” J of Biomedical Materials Research, vol. 47, Iss 4, Dec. 15, 1999, pp. 439-465.Applicant
Sellaro, Tiffany L., “Effects of Collagen Orientation on the Medium-Term Fatigue Response of Heart Valve Biomaterials” 2003, (published thesis) pp. 40-45.Applicant
Sellaro, Tiffany L. et al., “Effects of Collagen Fiber Orientation on the Response of Biologically Derived Soft Tissue Biomaterials to Cyclic Loading” J. Biomed Mater Res A, Jan. 1, 2007; 80(1): 194-205); published online Oct. 13, 2006 by Wiley InterScience.Applicant
Shandas, Robin PhD et al., “A Method for Determining the Reference Effective Flow Areas for Mechanical Heart Valve Prostheses” Circulation Apr. 25, 2000.Applicant
Shen, Ming et al., “Effect of ethanol and ether in the prevention of calcification of bioprostheses” Ann Thorac Surg. May 2001;71(5 Suppl):S413-6.Applicant
Shen, Ming et al., “Protein adsorption in glutaraldehyde-preserved bovine pericardium and porcine valve tissues” The Annals of Thoracic Surgery, 2001; 71:409-409.Applicant
Simionescu, D et al., “Mapping of glutaraldehyde-treated bovine pericardium and tissue selection for bioprosthetic heart valve” J. Biomed Mater Res, Jun. 1, 1993:27(6):697-704.Applicant
Sun, Wei et al., “Response of heterograft heart valve biomaterials to moderate cyclic loading” J Biomed Mater Res A, Jun. 2004, 69(4); 658-69.Applicant
Topol, Eric J., “Textbook of Interventional Cardiology”, 1990, Chs. 43-44, pp. 831-867.Applicant
Vyavahare, Narendra et al., “Mechanisms of bioprosthetic heart valve failure: Fatigue causes collagen denaturation and glycosaminoglysan loss” J of Biomedical Research, vol. 446, Iss 1, Jul. 1999, pp. 44-50.Applicant
Vyavahare, NR et al., “Prevention of Glutaraldehyde-Fixed Bioprosthetic Heart Valve Calcification by Alcohol Pretreatment: Further Mechanistic Studies” J Heart Valve Dis. Jul. 2000;9(4):561-6.Applicant
Werner, S. et al., “Testing the Hydrodynamic properties of heart valve prostheses with a new test apparatus”, Biomed Tech (Berl) Sep. 1994; 30(9); pp. 204-210.Applicant
Wiegner, A W et al., “Mechanical and structural correlates of canine pericardium” Circ Res, Sep. 1, 1981m 49(3); 807-14.Applicant
Yasui, Takeshi et al., “Determination of collagen fiber orientation in human tissue by use of polarization measurement of molecular second-harmonic-generation light”, Applied Optics, vol. 42, No. 14, May 10, 2004, pp. 2861-2867.Applicant
Zioupos, P. et al., “Anisotropic Elasticity and Strength of Glutaraldehyde Fixed Bovine Pericardium for Use in Pericardial Bioprosthetic Valves” J. Biomed Mater Res., Jan. 1994, 28(1):49-57.Applicant
Zioupos, P. et al., “Mechanical and Optical anisotrophy of bovine pericardium” Med Biol Eng Comput, Jan. 1992; 30(1); pp. 76-82.Applicant
Supplemental Declaration Under 37 CFR 1.131 by inventors filed in U.S. Appl. No. 10/887,688, filed Dec. 15, 2008.Applicant
Office Action issued in U.S. Appl. No. 10/887,688, dated Nov. 28, 2007.Applicant
Final Office Action issued in U.S. Appl. No. 10/887,688, dated Jul. 15, 2008.Applicant
Office Action issued in U.S. Appl. No. 10/887,688, dated Mar. 16, 2009.Applicant
Examiner Interview Summary issued in U.S. Appl. No. 10/887,688, dated Jun. 12, 2009.Applicant
Final Office Action issued in U.S. Appl. No. 10/887,688, dated Mar. 2, 2010.Applicant
Supplemental Declaration Under 37 CFR 1.131 by inventors filed in U.S. Appl. No. 10/887,688, filed Sep. 14, 2009.Applicant
Supplemental Declaration Under 37 CFR 1.131 by inventors filed in U.S. Appl. No. 10/887,688, filed Feb. 28, 2008.Applicant
Examiner Interview Summary issued in U.S. Appl. No. 10/887,688, dated Jul. 26, 2010.Applicant
Office Action issued in U.S. Appl. No. 10/887,688, dated Feb. 16, 2012.Applicant
Office Action issued Sep. 29, 2010, issued in U.S. Appl. No. 12/228,192.Applicant
Examiner Interview Summary, dated Apr. 5, 2011 in U.S. Appl. No. 12/228,192.Applicant
Final Office Action issued Jul. 14, 2011, in U.S. Appl. No. 12/228,192.Applicant
Office Action issued in U.S. Appl. No. 10/037,266, dated May 8, 2003.Applicant
Final Office Action issued in U.S. Appl. No. 10/037,266, dated Mar. 9, 2004.Applicant
PCT International Search Report and Written Opinion, in Application PCT/US2011/026763, dated Nov. 14, 2011.Applicant
PCT Written Opinion, in Application PCT/US2011/026741, dated Nov. 28, 2011.Applicant
Applicants' Reply to Written Opinion, filed Feb. 28, 2012, in App. PCT/US2011/026741.Applicant
Cross-reference is made to U.S. Appl. No. 13/367,252, filed Feb. 6, 2012.Applicant
Cross-reference is made to PCT Application No. PCT/US11/53120, filed on Sep. 23, 2011.Applicant
Cross-reference is made to U.S. Appl. No. 13/243,980, filed Sep. 23, 2011.Applicant
Cross-reference is made to PCT Application No. PCT/US11/64989, filed on Dec. 14, 2011.Applicant
Cross-reference is made to U.S. Appl. No. 13/171,400, filed Jun. 28, 2011.Applicant
PCT International Search Report and Written Opinion, in Application PCT/US2011/053120, dated Apr. 27, 2012.Applicant
Mendelson, Karen et al., “Heart Valve Tissue Engineering: Concepts, Approaches, Progress, and Challenges” Ann Biomed Eng, Dec. 2006; 34(12); pp. 1799-1819; published online Oct. 12, 2006 doi:10.1007/s/10439-006-9163-z.Applicant
Sacks, M S et al., “Bioprosthetic heart valve heterograft biomaterials: structure, mechanical behavior and computational simulation” Expert Rev Med Devices, Nov. 2006; 3(6): pp. 817-34 (Abstract only).Applicant
Schmidt, Dorthe et al., “Tissue engineering of heart valves using decellularized xenogeneic of polymeric starter matrices” Philos Trans R Soc Lond B Bio Sci., Aug. 29, 2007, 362(1484); 1505-1512; published online Jun. 22, 2007, doi: 10.1098/rstb.2007.2131.Applicant
Examination Report in Australian Application No. 2011343755, dated May 13, 2014.Applicant
Affidavit of Dr. Paolo Angelini, M.D., signed Aug. 25, 2009.Applicant
Affidavit of Dr. Gervasio A. Lamas, M.D., signed Sep. 3, 2009.Applicant
Andersen, H.R. et al., “Transluminal implantation of artificial heart valve” European Heart Journal, 1992, 13, pp. 704-708.Applicant
“Artificial heart valve” http://en.wikipedia.org/Artificial—heart—valve, printed May 13, 2009.Applicant
Bonhoeffer, Philipp M.D. et al., “Percutaneous Insertion of the Pulmonary Valve” J of the Amer College of Cardiology, vol. 39, No. 10, Elsevier Science, Inc. 2002, pp. 1664-1669, London, UK, and Paris, FR.Applicant
Bonhoeffer, Philipp et al., “Percutaeous replacement of pulmonary valve in a right-centricle to pulmonary-artery prosthetic conduit with valve dysfunction” Early Report, The Lacet, vol. 356, Oct. 21, 2000, p. 1403-1405.Applicant
Bonhoeffer, Philipp et al., “Transcatherter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study” Circulation J. of the Amer Heart Assoc, 2000; 102; 813-816.Applicant
Boudjemline, Younes et al., “Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: An experimental study” J. Am. Coll. Cardiol. 2004; 43; 1082-1087.Applicant
Braga-Vilela, A. et al., “Extracellular Matrix of Porcine Pericardium; Biochemistry and Collagen Architecture” J. Membr Biol., 2008.Applicant
Breuer, Christopher K. M.D. et al., “Application of Tissue-Engineering Principles toward the Development of a Semilunar Heart Valve Substitute” Tissue Engineering, vol. 10, No. 11/12, 2004 pp. 1725-1736.Applicant
Cale, A.R. et al., “Revisited: a descending thorasic aortic valve to treat prosthetic valve insufficiency” Ann Thorac Surg, May 1993, 55(5), pp. 1218-1212.Applicant
Cerrolaza, M et al., “A comparison of the hydrodynamical behaviour of three heart aortic prostheses by numerical methods”.Applicant
“Collagen” http://en.wikipedia.org/wiki/Collagen, printed May 13, 2009.Applicant
Collins, J. J., Jr, “The Evolution of artificial heart valve” N. Engl J Med, Feb. 28, 1991; 324(9):624-6.Applicant
Corden, J. et al., “The influence of open leaflet geometry on the haemodynamic flow characteristics of polyrethane trileaflet artificial heart valve” PubMed medline query, p. 1 of 1.Applicant
Cribier, Alain et al., “Percutaneious Transcatheter Implantation of an Aoritc Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description” Circulation J of the Amer Heart Assoc, originally published online Nov. 25, 2002.Applicant
Edwards Lifesciences Receives FDA Approval for New Heart Valve, http:www.medicalnewstoday.com/articles/149588.php, dated May 11, 2009.Applicant
Fish, R. David, “Percutaneous Heart Valve Replacement: Enthusiasm Tempered” Circulation J of the Amer Heart Assoc, 2004; 110; 1876-1878.Applicant
Fishbein, M.C. et al., “Cardiac pathology after aortic valve replacement using Hufnagel trileaflet prostheses: study of 20 necropsy patients” Ann Heart J., Apr. 1975, 89(4), pp. 443-448.Applicant
Gloeckner, D. Claire et al., “Mechanical Evaluation and Design of a Multilayered Collagenous Repair Biomaterial” J. of Biomedical Materials Research Part A, vol. 52 Iss 2, pp. 365-373, Published online Aug. 15, 2000, Wiley Periodicals, Inc.Applicant
Grube E., et al., “Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System”, Circ. Cardiovasc Intervent. 2008;1:167-175 (abstract).Applicant
Hanlon, JG et al., “Pre-use intraoperative testing of autologous tissue for valvular surgery: a proof of concept study” J. Heart Valve Dis, Nov. 1999; 8(6); pp. 614-623.Applicant
Bech-Hanssen, Odd, M.D. et al., “Aortic Prosthetic Valve Desing and Size: Relation to Doppler Echocardiographic Finding and Pressure Recovery—An In Vitro Study” J. Am Soc Echocardiography 2000; 13:39-50.Applicant
Hasenkam, J.M. et al., “A model for acute haemodynamic studies in the ascending aorta in pigs” Cardiovasc Res, Jul. 1988, 22(7), pp. 464-471.Applicant
Hiester,E.D. et al., “Optimal bovine pericardial tissue selection sites. I. Fiber architecture and tissue thickness measurements.” J. Biomed Mater Res, Feb. 1, 1998; 39(2):207-14.Applicant
Hufnagel, Charles A., M.D., “Basic Concepts in the Development of Cardiovascular Prosthes” The American Journal of Surgery, vol. 137, Mar. 1979.Applicant
Hufnagel, Charles.A., MD et al., “In the beginning. Surgical Correction of Aortic Insufficiency” 1954; Ann Thorac Surg May 1989; 47(3), pp. 475-476.Applicant
Hufnagel, Charles.A., MD et al., “Late follow-up of ball-valve prostheses in the descending thoracic aortia”, J. Throrac Cardiovasc Surg, Dec. 1976, 72(6), pp. 900-909.Applicant
Hufnagel, Charles.A., MD et al., “Surgical Correction of Aortic Insufficiency” Surgery vol. 35, May 1954 No. 5.Applicant
Hufnagel, Charles A., “Vessels and Valves”, Sec. 1: Development of Cardiac Surgery, Chap 7, pp. 43-55.Applicant
“Introduction to Stereomicroscopy”, http://www.microscopyu.com/articles/stereomicroscopy/stereointro.html, May 13, 2009.Applicant
IOPATCH(R) Tutoplast(R) Processed Pericardium Directions for Use; http://www.iopinc.com/surgeons—and—medical—professionals/iopatch/directions.asp, printed on Jun. 2, 2009.Applicant
Knudsen, LL et al., “Catheter-implanted prosthetic heart valves. Transluminal catheter implantation of a new expandable artificial heart valve in the descending thoracic aorta in isolated vessels and closed chest pigs” Int J. Artif Organs, May 1993, 16(5); pp. 253-262.Applicant
Lax, Jorge A., M.D., et al. “Estimation of the Ejection Fraction in Patients with Myocardial Infarction Obtained from the Combined Index of Systolic and Diastolic Left Ventricular Function: A New Method” J of the American Soc of Echocardiography, vol. 13, No. 2.Applicant
Liao, Jun et al., “Molecular orientation of collagen in intact planar connective tissues under biaxial stretch” Acta Biomateriala, vol. 1, Iss. 1, Jan. 2005, pp. 45-54.Applicant
Liao, K X et al., “Two-dimensional mechanical and ultrastructural correlates of bovine pericardium for prosthetic valves” ASAIO Trans, Jun. 1, 1991, 37(3); M341-51.Applicant
Ls, Yu et al., “New Polyurethane valves in new soft artificial heart” ASAIO Trans Jul.-Sep. 1989; 35(3), pp. 301-304.Applicant
Mirnajafi, A. et al. “The effects of collagen fiber orientation of the flexural properties of pericardial heterograft biomaterials” Biomaterials, Mar. 2005; 26(7): 795-804.Applicant
Mirzaie, M. et al., “A new storage solution for porcine aortic valves” Ann Thorac Cardiovasc Surg. Apr. 2007;13(2):102-9.Applicant
Moazami, N. et al., “Transluminal aortic valve placement. A feasibility study with a newly designed collapsible aortic valve” ASAIO J, Sep.-Oct. 1996, 42(5):M 381-5.Applicant
Nienaber C., M.D. et al., “Nonsurgical Reconstruction of Thoracic Aortic Dissection by Stent-Graft Placement” N. Eng. J. Med, May 20, 1999, col. 340, No. 20.Applicant
Noorlander, Maril L. et al., “A Quantitative Method to Determine the Orientation of Collagen Fibers in the Dermis” The J. of Histochemistry & Cytochemistry, vol. 50(11): 2002, pp. 1469-1474.Applicant
Nunn, D.B., “Structural Failure of Dacron Arterial Grafts” Seminars in Vascular Surgery, col. 12, No. 1 (Mar. 1999), pp. 88-91.Applicant
Optical Microscope, Wikipedia, http://en.wikipedia.org/wiki/Stereomiscroscope, May 13, 2009.Applicant
Orthogonality, http://en.wikipedia.org/wiki/Orthogonal, May 13, 2009.Applicant
Paniagua, David, et al., Percutaneous Heart Valve in the Chronic In Vitro Testing Model, Circulation, 2002, pp. e51-e52, vol. 106, American Heart Association, US.Applicant
Paniagua, David et al., First Human Case of Retrograde Transcatheter Implantation of an Aortic Valve Prosthesis, Texas Heart Institute Journal, 2005, pp. 91-96, vol. 32, US.Applicant
“Pathak, CP et al., ““Treatment of bioprosthetic heart valve tissue with long chain alcohol solution to lowercalcification potential”” J Biomed Mater Res A. Apr. 1, 2004;69(1):140-4”.Applicant
Pavenik, Susan, M.D., PhD et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatherter Placement” Cardivascular Radiology, Apr. 1992, pp. 151-154.Applicant
Pick, Adam, “True or False: An Edwards Lifescience' Tissue Valve Replacement Requires 1,800 Hand-Sewn Stitches” http://heart-valve-surgery.com/heart-surgery-blog/2008/02/26. printed Aug. 13, 2010.Applicant
PCT International Search Report and Written Opinion, in Application PCT/US2011/042252, dated Apr. 6, 2011.Applicant
Office Action in Chinese Application No. 201180067413.6, dated Jan. 21, 2015.Applicant
Declaration Under 37 CFR 1.131 as filed in U.S. Appl. No. 10/887,688 on Dec. 15, 2008, by co-inventors of that application. (Best available copy).Applicant
Second Examination Report in Australian Application No. 2011343755, dated Aug. 29, 2014.Applicant
Chew, G.G. et al., “Simulation of Damage in a Porcine Prosthetic Heart Valve” J. Med. Eng. Technol., Sep.-Oct. 1999; 23(5): pp. 178-189 (Abstract of article).Applicant
Christie G.W. et al., “On Stress Reduction in Bioprosthetic Heart Valve Leaflets by the Use of a Flexible Stent” J. Card Surg, Dec. 1991; 6(4) pp. 476-481 (Abstract of article).Applicant
Non-Final Office Action issued Mar. 6, 2013 in U.S. Appl. No. 13/723,541.Applicant
Examination Report No. 1 issued dated Feb. 20, 2013 in Australian Application No. 2011223708.Applicant
Final Office Action issued Mar. 20, 2013 in U.S. Appl. No. 13/038,260.Applicant
Hilbert et al., “Biomechanics: Allograft Heart Valves,” Cardiac Reconstructions with Allograft Tissues, Springer, New York (2005), pp. 210-212.Applicant
Non-Final Office Action issued in U.S. Appl. No. 13/038,260, dated Jun. 29, 2012.Applicant
PCT International Search Report and Written Opinion, in Application PCT/US2011/064989, dated Jun. 28, 2012.Applicant
Paniagua, David et al., Abstract 4622: “Percutaneous Implantation of a Low Profile, Dry Membrane, Heart Valve in an Integrated Delivery System in the Aortic and Pulmonary Positions: One-month Animal Results,” Circulation, American Heart Association, Inc., 2009; 120: S982.Applicant
Notice of Allowance and Examiner Initiated Interview Summary issued in U.S. Appl. No. 13/038,361, dated Dec. 18, 2012.Applicant
PCT International Report on Patentability in Application No. PCT/US2011/064989, issued Jun. 27, 2013.Applicant